<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BIAXIN - clarithromycin tablet, film coated </strong><br><strong>BIAXIN - clarithromycin tablet, film coated, extended release </strong><br><strong>BIAXIN - clarithromycin granule, for suspension </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>BIAXIN® Filmtab®<br>(clarithromycin tablets, USP)<br>BIAXIN® XL Filmtab®<br>(clarithromycin extended-release tablets)<br>BIAXIN® Granules<br>(clarithromycin for oral suspension, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN67538"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of BIAXIN and other antibacterial drugs, BIAXIN should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="GN67561"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Clarithromycin is a semi-synthetic macrolide antibiotic.  Chemically, it is 6-<span class="Italics">0</span>-methylerythromycin.  The molecular formula is C<span class="Sub">38</span>H<span class="Sub">69</span>NO<span class="Sub">13</span>, and the molecular weight is 747.96.  The structural formula is: </p>
<div class="Figure"><img alt="Chemical structure for clarithromycin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6&amp;name=biaxin-tab-stucture.jpg"></div>
<p>Clarithromycin is a white to off-white crystalline powder.  It is soluble in acetone, slightly soluble in methanol, ethanol, and acetonitrile, and practically insoluble in water.</p>
<p>BIAXIN is available as immediate-release tablets, extended-release tablets, and granules for oral suspension.</p>
<p>Each yellow oval film-coated immediate-release BIAXIN tablet (clarithromycin tablets, USP) contains 250 mg or 500 mg of clarithromycin and the following inactive ingredients:</p>
<p>250 mg tablets:  hypromellose, hydroxypropyl cellulose, croscarmellose sodium, D&amp;C Yellow No. 10, FD&amp;C Blue No. 1, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, propylene glycol, silicon dioxide, sorbic acid, sorbitan monooleate, stearic acid, talc, titanium dioxide, and vanillin.</p>
<p>500 mg tablets:  hypromellose, hydroxypropyl cellulose, colloidal silicon dioxide, croscarmellose sodium, D&amp;C Yellow No. 10, magnesium stearate, microcrystalline cellulose, povidone, propylene glycol, sorbic acid, sorbitan monooleate, titanium dioxide, and vanillin. </p>
<p>Each yellow oval film-coated BIAXIN XL tablet (clarithromycin extended-release tablets) contains 500 mg of clarithromycin and the following inactive ingredients:  cellulosic polymers, D&amp;C Yellow No. 10, lactose monohydrate, magnesium stearate, propylene glycol, sorbic acid, sorbitan monooleate, talc, titanium dioxide, and vanillin.</p>
<p>After constitution, each 5 mL of BIAXIN suspension (clarithromycin for oral suspension, USP) contains 125 mg or 250 mg of clarithromycin.  Each bottle of BIAXIN granules contains 1250 mg (50 mL size), 2500 mg (50 and 100 mL sizes) or 5000 mg (100 mL size) of clarithromycin and the following inactive ingredients:  carbomer, castor oil, citric acid, hypromellose phthalate, maltodextrin, potassium sorbate, povidone, silicon dioxide, sucrose, xanthan gum, titanium dioxide and fruit punch flavor.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="GN67645"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="GN67665"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Clarithromycin is rapidly absorbed from the gastrointestinal tract after oral administration.  The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.  For a single 500 mg dose of clarithromycin, food slightly delays the onset of clarithromycin absorption, increasing the peak time from approximately 2 to 2.5 hours.  Food also increases the clarithromycin peak plasma concentration by about 24%, but does not affect the extent of clarithromycin bioavailability.  Food does not affect the onset of formation of the antimicrobially active metabolite, 14-OH clarithromycin or its peak plasma concentration but does slightly decrease the extent of metabolite formation, indicated by an 11% decrease in area under the plasma concentration-time curve (AUC).  Therefore, BIAXIN tablets may be given without regard to food.</p>
<p>In nonfasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.  Steady-state peak plasma clarithromycin concentrations were attained within 3 days and were approximately 1 to 2 µg/mL with a 250 mg dose administered every 12 hours and 3 to 4 µg/mL with a 500 mg dose administered every 8 to 12 hours.  The elimination half-life of clarithromycin was about 3 to 4 hours with 250 mg administered every 12 hours but increased to 5 to 7 hours with 500 mg administered every 8 to 12 hours.  The nonlinearity of clarithromycin pharmacokinetics is slight at the recommended doses of 250 mg and 500 mg administered every 8 to 12 hours.  With a 250 mg every 12 hours dosing, the principal metabolite, 14-OH clarithromycin, attains a peak steady-state concentration of about 0.6 µg/mL and has an elimination half-life of 5 to 6 hours.  With a 500 mg every 8 to 12 hours dosing, the peak steady-state concentration of 14-OH clarithromycin is slightly higher (up to 1 µg/mL), and its elimination half-life is about 7 to 9 hours.  With any of these dosing regimens, the steady-state concentration of this metabolite is generally attained within 3 to 4 days.</p>
<p>After a 250 mg tablet every 12 hours, approximately 20% of the dose is excreted in the urine as clarithromycin, while after a 500 mg tablet every 12 hours, the urinary excretion of clarithromycin is somewhat greater, approximately 30%.  In comparison, after an oral dose of 250 mg (125 mg/5 mL) suspension every 12 hours, approximately 40% is excreted in urine as clarithromycin.  The renal clearance of clarithromycin is, however, relatively independent of the dose size and approximates the normal glomerular filtration rate.  The major metabolite found in urine is 14-OH clarithromycin, which accounts for an additional 10% to 15% of the dose with either a 250 mg or a 500 mg tablet administered every 12 hours.</p>
<p>Steady-state concentrations of clarithromycin and 14-OH clarithromycin observed following administration of 500 mg doses of clarithromycin every 12 hours to adult patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> were similar to those observed in healthy volunteers.  In adult HIV-infected patients taking 500- or 1000-mg doses of clarithromycin every 12 hours, steady-state clarithromycin C<span class="Sub">max</span> values ranged from 2 to 4 µg/mL and 5 to 10 µg/mL, respectively.</p>
<p>The steady-state concentrations of clarithromycin in subjects with impaired hepatic function did not differ from those in normal subjects; however, the 14-OH clarithromycin concentrations were lower in the hepatically impaired subjects.  The decreased formation of 14-OH clarithromycin was at least partially offset by an increase in renal clearance of clarithromycin in the subjects with impaired hepatic function when compared to healthy subjects.</p>
<p>The pharmacokinetics of clarithromycin was also altered in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  (See <span class="Bold">PRECAUTIONS  </span>and <span class="Bold">DOSAGE AND ADMINISTRATION</span>.)</p>
<p>Clarithromycin and the 14-OH clarithromycin metabolite distribute readily into body tissues and fluids.  There are no data available on cerebrospinal fluid penetration.  Because of high intracellular concentrations, tissue concentrations are higher than serum concentrations.  Examples of tissue and serum concentrations are presented below.</p>
<a name="table_1"></a><table width="100%">
<caption><span>CONCENTRATION (after 250 mg q12h)</span></caption>
<colgroup>
<col align="left" width="32%">
<col width="34%">
<col width="32%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule" align="left"><span class="Bold"> Tissue Type</span></td>
<td class="Botrule Toprule" align="center">
<span class="Bold">Tissue<br></span>(µg/g)</td>
<td class="Botrule Toprule" align="center">
<span class="Bold">Serum<br></span>(µg/mL)</td>
</tr>
<tr>
<td align="left">Tonsil</td>
<td align="center">1.6</td>
<td align="center">0.8</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left">Lung</td>
<td class="Botrule" align="center">8.8</td>
<td class="Botrule" align="center">1.7</td>
</tr>
</tbody>
</table>
<p>Clarithromycin extended-release tablets provide extended absorption of clarithromycin from the gastrointestinal tract after oral administration.  Relative to an equal total daily dose of immediate-release clarithromycin tablets, clarithromycin extended-release tablets provide lower and later steady-state peak plasma concentrations but equivalent 24-hour AUC's for both clarithromycin and its microbiologically-active metabolite, 14-OH clarithromycin.  While the extent of formation of 14-OH clarithromycin following administration of BIAXIN XL tablets (2 x 500 mg once daily) is not affected by food, administration under fasting conditions is associated with approximately 30% lower clarithromycin AUC relative to administration with food.  Therefore, BIAXIN XL tablets should be taken with food.</p>
<p><span class="Bold">Steady-State Clarithromycin Plasma Concentration-Time Profiles</span></p>
<div class="Figure"><img alt="Steady State Graph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6&amp;name=biaxin-tabs-steady-graph.jpg"></div>
<p>In healthy human subjects, steady-state peak plasma clarithromycin concentrations of approximately 2 to 3 µg/mL were achieved about 5 to 8 hours after oral administration of 2 x 500 mg BIAXIN XL tablets once daily; for 14-OH clarithromycin, steady-state peak plasma concentrations of approximately 0.8 µg/mL were attained about 6 to 9 hours after dosing.  Steady-state peak plasma clarithromycin concentrations of approximately 1 to 2 µg/mL were achieved about 5 to 6 hours after oral administration of a single 500 mg BIAXIN XL tablet once daily; for 14-OH clarithromycin, steady-state peak plasma concentrations of approximately 0.6 µg/mL were attained about 6 hours after dosing.</p>
<p>When 250 mg doses of clarithromycin as BIAXIN suspension were administered to fasting healthy adult subjects, peak plasma concentrations were attained around 3 hours after dosing.  Steady-state peak plasma concentrations were attained in 2 to 3 days and were approximately 2 µg/mL for clarithromycin and 0.7 µg/mL for 14-OH clarithromycin when 250-mg doses of the clarithromycin suspension were administered every 12 hours.  Elimination half-life of clarithromycin (3 to 4 hours) and that of 14-OH clarithromycin (5 to 7 hours) were similar to those observed at steady state following administration of equivalent doses of BIAXIN tablets.</p>
<p>For adult patients, the bioavailability of 10 mL of the 125 mg/5 mL suspension or 10 mL of the 250 mg/5 mL suspension is similar to a 250 mg or 500 mg tablet, respectively.</p>
<p>In children requiring antibiotic therapy, administration of 7.5 mg/kg q12h doses of clarithromycin as the suspension generally resulted in steady-state peak plasma concentrations of 3 to 7 µg/mL for clarithromycin and 1 to 2 µg/mL for 14-OH clarithromycin.</p>
<p>In HIV-infected children taking 15 mg/kg every 12 hours, steady-state clarithromycin peak concentrations generally ranged from 6 to 15 µg/mL.</p>
<p>Clarithromycin penetrates into the middle ear fluid of children with secretory <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>.</p>
<a name="table_2"></a><table width="100%">
<caption><span>CONCENTRATION (after 7.5 mg/kg q12h for 5 doses)</span></caption>
<colgroup>
<col align="left" width="30%">
<col width="34%">
<col width="34%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule" align="left"><span class="Bold">Analyte</span></td>
<td class="Botrule Toprule" align="center">
<span class="Bold">Middle Ear Fluid<br></span>(µg/mL)</td>
<td class="Botrule Toprule" align="center">
<span class="Bold">Serum<br></span>(µg/mL)</td>
</tr>
<tr>
<td align="left">Clarithromycin</td>
<td align="center">2.5</td>
<td align="center">1.7</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left">14-OH Clarithromycin</td>
<td class="Botrule" align="center">1.3</td>
<td class="Botrule" align="center">0.8</td>
</tr>
</tbody>
</table>
<p>In adults given 250 mg clarithromycin as suspension (n = 22), food appeared to decrease mean peak plasma clarithromycin concentrations from 1.2 (± 0.4) µg/mL to 1.0 (± 0.4) µg/mL and the extent of absorption from 7.2 (± 2.5) hr<span class="Bold">•  </span>µg/mL to 6.5 (± 3.7) hr<span class="Bold">•  </span>µg/mL.</p>
<p>When children (n = 10) were administered a single oral dose of 7.5 mg/kg suspension, food increased mean peak plasma clarithromycin concentrations from 3.6 (± 1.5) µg/mL to 4.6 (± 2.8) µg/mL and the extent of absorption from 10.0 (± 5.5) hr<span class="Bold">•</span>µg/mL to 14.2 (± 9.4) hr<span class="Bold">•</span>µg/mL.</p>
<p>Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult males.  The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole.  For clarithromycin, the mean C<span class="Sub">max</span> was 10% greater, the mean C<span class="Sub">min</span> was 27% greater, and the mean AUC<span class="Sub">0-8</span> was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone.  Similar results were seen for 14-hydroxy-clarithromycin, the mean C<span class="Sub">max</span> was 45% greater, the mean C<span class="Sub">min</span> was 57% greater, and the mean AUC<span class="Sub">0-8 </span>was 45% greater.  Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.</p>
<a name="table_3"></a><table width="100%">
<caption><span>Clarithromycin Tissue Concentrations 2 hours after Dose (µg/mL)/(µg/g)</span></caption>
<colgroup>
<col width="30%">
<col align="center" width="6%">
<col align="center" width="18%">
<col align="center" width="19%">
<col align="center" width="5%">
<col align="center" width="19%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule"><span class="Bold">Treatment</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">N</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">antrum</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">fundus</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">N</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">mucus</span></td>
</tr>
<tr>
<td>Clarithromycin</td>
<td align="center">5</td>
<td align="center">10.48 ± 2.01</td>
<td align="center">20.81 ± 7.64</td>
<td align="center">4</td>
<td align="center">4.15 ± 7.74</td>
</tr>
<tr class="Last">
<td class="Botrule">Clarithromycin + Omeprazole</td>
<td class="Botrule" align="center">5</td>
<td class="Botrule" align="center">19.96 ± 4.71</td>
<td class="Botrule" align="center">24.25 ± 6.37</td>
<td class="Botrule" align="center">4</td>
<td class="Botrule" align="center">39.29 ± 32.79</td>
</tr>
</tbody>
</table>
<p>For information about other drugs indicated in combination with BIAXIN, refer to the <span class="Bold">CLINICAL PHARMACOLOGY  </span> section of their package inserts.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="GN68110"></a><a name="section-3.2"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Clarithromycin exerts its antibacterial action by binding to the 50S ribosomal subunit of susceptible microorganisms resulting in inhibition of protein synthesis.</p>
<p>Clarithromycin is active <span class="Italics">in vitro</span> against a variety of aerobic and anaerobic gram-positive and gram-negative microorganisms as well as most <span class="Italics">Mycobacterium avium</span> complex (MAC) microorganisms.</p>
<p>Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity.  The 14-OH clarithromycin is twice as active against <span class="Italics">Haemophilus influenzae  </span> microorganisms as the parent compound.  However, for <span class="Italics">Mycobacterium avium</span> complex (MAC) isolates the 14-OH metabolite is 4 to 7 times less active than clarithromycin.  The clinical significance of this activity against <span class="Italics">Mycobacterium avium</span> complex is unknown.</p>
<p>Clarithromycin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold">INDICATIONS AND USAGE</span> section:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="GN68171"></a><a name="section-3.2.1"></a><p></p>
<h3>Aerobic Gram-positive Microorganisms</h3>
<p class="First"><span class="Italics">Staphylococcus aureus<br>Streptococcus pneumoniae<br>Streptococcus pyogenes</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN68205"></a><a name="section-3.2.2"></a><p></p>
<h3>Aerobic Gram-negative Microorganisms</h3>
<p class="First"><span class="Italics">Haemophilus influenzae<br>Haemophilus parainfluenzae<br>Moraxella catarrhalis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN68239"></a><a name="section-3.2.3"></a><p></p>
<h3>Other Microorganisms</h3>
<p class="First"><span class="Italics">Mycoplasma pneumoniae<br>Chlamydia pneumoniae</span> (TWAR)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN68271"></a><a name="section-3.2.4"></a><p></p>
<h3>Mycobacteria</h3>
<p class="First"><span class="Italics">Mycobacterium avium</span> complex (MAC) consisting of:<br> <span class="Italics">Mycobacterium avium<br> Mycobacterium intracellulare</span></p>
<p>Beta-lactamase production should have no effect on clarithromycin activity.</p>
<p><span class="Bold">NOTE:  </span>  Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of methicillin-resistant and oxacillin-resistant staphylococci are resistant to clarithromycin.</p>
<p>Omeprazole/clarithromycin dual therapy; ranitidine bismuth citrate/clarithromycin dual therapy; omeprazole/clarithromycin/amoxicillin triple therapy; and lansoprazole/clarithromycin/amoxicillin triple therapy have been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Helicobacter pylori in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold">INDICATIONS AND USAGE</span> section.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN68330"></a><a name="section-3.2.5"></a><p></p>
<h3>Helicobacter</h3>
<p class="First"><span class="Italics">Helicobacter pylori  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN68359"></a><a name="section-3.2.6"></a><p></p>
<h3>Pretreatment Resistance</h3>
<p class="First">Clarithromycin pretreatment resistance rates were 3.5% (4/113) in the omeprazole/clarithromycin dual therapy studies (M93-067, M93-100) and 9.3% (41/439) in the omeprazole/clarithromycin/amoxicillin triple therapy studies (126, 127, M96-446).  Clarithromycin pretreatment resistance was 12.6% (44/348) in the ranitidine bismuth citrate/clarithromycin b.i.d. versus t.i.d. clinical study (H2BA3001).  Clarithromycin pretreatment resistance rates were 9.5% (91/960) by E-test and 11.3% (12/106) by agar dilution in the lansoprazole/clarithromycin/amoxicillin triple therapy clinical trials (M93-125, M93-130, M93-131, M95-392, and M95-399).</p>
<p>Amoxicillin pretreatment susceptible isolates (&lt; 0.25 µg/mL) were found in 99.3% (436/439) of the patients in the omeprazole/clarithromycin/amoxicillin clinical studies (126, 127, M96-446).  Amoxicillin pretreatment <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) &gt; 0.25 µg/mL occurred in 0.7% (3/439) of the patients, all of whom were in the clarithromycin/amoxicillin study arm.  Amoxicillin pretreatment susceptible isolates (&lt; 0.25 µg/mL) occurred in 97.8% (936/957) and 98.0% (98/100) of the patients in the lansoprazole/clarithromycin/amoxicillin triple-therapy clinical trials by E-test and agar dilution, respectively.  Twenty-one of the 957 patients (2.2%) by E-test and 2 of 100 patients (2.0%) by agar dilution had amoxicillin pretreatment MICs of &gt; 0.25 µg/mL.  Two patients had an unconfirmed pretreatment amoxicillin <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) of &gt; 256 µg/mL by E-test.</p>
<a name="table_4"></a><table width="100%">
<caption><span>Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes<span class="Sup">a</span></span></caption>
<colgroup>
<col width="21%">
<col width="505*">
<col width="23%">
<col width="1129*">
<col width="1069*">
<col width="832*">
<col width="1022*">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><span class="Bold">Clarithromycin Pretreatment Results</span></td>
<td class="Toprule" align="center" valign="top"> </td>
<td class="Toprule" align="center" colspan="5" valign="top"><span class="Bold">Clarithromycin Post-treatment Results</span></td>
</tr>
<tr valign="bottom">
<td valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top">
<span class="Italics"><span class="Bold">H. pylori</span></span><span class="Bold"> negative - eradicated</span>
</td>
<td align="center" colspan="4" valign="top">
<span class="Italics"><span class="Bold">H. pylori</span></span><span class="Bold"> positive - not eradicated                <br>Post-treatment susceptibility results</span>
</td>
</tr>
<tr valign="bottom">
<td class="Botrule"> </td>
<td class="Botrule" align="center"> </td>
<td class="Botrule" align="center"> </td>
<td class="Botrule" align="center" valign="top"><span class="Bold">S<span class="Sup">b</span></span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">I<span class="Sup">b</span></span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">R<span class="Sup">b</span></span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">No MIC</span></td>
</tr>
<tr><td colspan="7"><span class="Bold">Omeprazole 40 mg q.d./clarithromycin 500 mg t.i.d. for 14 days followed by omeprazole 20 mg q.d. for another 14 days (M93-067, M93-100)</span></td></tr>
<tr>
<td>Susceptible<span class="Sup">b</span>
</td>
<td align="center">108</td>
<td align="center">72</td>
<td align="center">1</td>
<td align="center"> </td>
<td align="center">26</td>
<td align="center">9</td>
</tr>
<tr>
<td>Intermediate<span class="Sup">b</span>
</td>
<td align="center">1</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center">1</td>
<td align="center"> </td>
</tr>
<tr>
<td>Resistant<span class="Sup">b</span>
</td>
<td align="center">4</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center">4</td>
<td align="center"> </td>
</tr>
<tr><td colspan="7"><span class="Bold">Ranitidine bismuth citrate 400 mg b.i.d./clarithromycin 500 mg t.i.d. for 14 days followed by ranitidine bismuth citrate 400 mg b.i.d. for another 14 days (H2BA3001)</span></td></tr>
<tr>
<td>Susceptible<span class="Sup">b</span>
</td>
<td align="center">124</td>
<td align="center">98</td>
<td align="center">4</td>
<td align="center"> </td>
<td align="center">14</td>
<td align="center">8</td>
</tr>
<tr>
<td>Intermediate<span class="Sup">b</span>
</td>
<td align="center">3</td>
<td align="center">2</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center">1</td>
</tr>
<tr>
<td>Resistant<span class="Sup">b</span>
</td>
<td align="center">17</td>
<td align="center">1</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center">15</td>
<td align="center">1</td>
</tr>
<tr><td colspan="7"><span class="Bold">Ranitidine bismuth citrate 400 mg b.i.d./clarithromycin 500 mg b.i.d. for 14 days followed by ranitidine bismuth citrate 400 mg b.i.d. for another 14 days (H2BA3001)</span></td></tr>
<tr>
<td>Susceptible</td>
<td align="center">125</td>
<td align="center">106</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">12</td>
<td align="center">5</td>
</tr>
<tr>
<td>Intermediate<span class="Sup">b</span>
</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>Resistant<span class="Sup">b</span>
</td>
<td align="center">20</td>
<td align="center">1</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center">19</td>
<td align="center"> </td>
</tr>
<tr><td colspan="7"><span class="Bold">Omeprazole 20 mg b.i.d./clarithromycin 500 mg b.i.d./amoxicillin 1 g b.i.d. for 10 days (126, 127, M96-446)</span></td></tr>
<tr>
<td>Susceptible<span class="Sup">b</span>
</td>
<td align="center">171</td>
<td align="center">153</td>
<td align="center">7</td>
<td align="center"> </td>
<td align="center">3</td>
<td align="center">8</td>
</tr>
<tr>
<td>Intermediate<span class="Sup">b</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>Resistant<span class="Sup">b</span>
</td>
<td align="center">14</td>
<td align="center">4</td>
<td align="center">1</td>
<td align="center"> </td>
<td align="center">6</td>
<td align="center">3</td>
</tr>
<tr><td colspan="7"><span class="Bold">Lansoprazole 30 mg b.i.d./clarithromycin 500 mg b.i.d./amoxicillin 1 g b.i.d. for 14 days (M95-399, M93-131, M95-392)</span></td></tr>
<tr>
<td>Susceptible<span class="Sup">b</span>
</td>
<td align="center">112</td>
<td align="center">105</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center">7</td>
</tr>
<tr>
<td>Intermediate<span class="Sup">b</span>
</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>Resistant<span class="Sup">b</span>
</td>
<td align="center">17</td>
<td align="center">6</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center">7</td>
<td align="center">4</td>
</tr>
<tr><td colspan="7"><span class="Bold">Lansoprazole 30 mg b.i.d./clarithromycin 500 mg b.i.d./amoxicillin 1 g b.i.d. for 10 days (M95-399)</span></td></tr>
<tr>
<td>Susceptible<span class="Sup">b</span>
</td>
<td align="center">42</td>
<td align="center">40</td>
<td align="center">1</td>
<td align="center"> </td>
<td align="center">1</td>
<td align="center"> </td>
</tr>
<tr>
<td>Intermediate<span class="Sup">b</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>Resistant<span class="Sup">b</span>
</td>
<td align="center">4</td>
<td align="center">1</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center">3</td>
<td align="center"> </td>
</tr>
<tr class="Last"><td class="Toprule" colspan="7">a   Includes only patients with pretreatment clarithromycin susceptibility tests<br>b   Susceptible (S) MIC &lt; 0.25 µg/mL, Intermediate (I) MIC 0.5-1.0 µg/mL, Resistant (R) MIC &gt; 2 µg/mL</td></tr>
</tbody>
</table>
<p>Patients not eradicated of <span class="Italics">H. pylori</span> following omeprazole/clarithromycin, ranitidine bismuth citrate/clarithromycin, omeprazole/clarithromycin/amoxicillin, or lansoprazole/clarithromycin/ amoxicillin therapy would likely have clarithromycin resistant <span class="Italics">H. pylori</span> isolates.  Therefore, for patients who fail therapy, clarithromycin susceptibility testing should be done, if possible.  Patients with clarithromycin resistant <span class="Italics">H. pylori</span> should not be treated with any of the following:  omeprazole/clarithromycin dual therapy; ranitidine bismuth citrate/clarithromycin dual therapy; omeprazole/clarithromycin/amoxicillin triple therapy; lansoprazole/clarithromycin/amoxicillin triple therapy; or other regimens which include clarithromycin as the sole antimicrobial agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN69169"></a><a name="section-3.2.7"></a><p></p>
<h3>Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes</h3>
<p class="First">In the omeprazole/clarithromycin/amoxicillin triple-therapy clinical trials, 84.9% (157/185) of the patients who had pretreatment amoxicillin susceptible MICs (&lt; 0.25 µg/mL) were eradicated of <span class="Italics">H. pylori</span> and 15.1% (28/185) failed therapy.  Of the 28 patients who failed triple therapy, 11 had no post-treatment susceptibility test results, and 17 had post-treatment <span class="Italics">H. pylori</span> isolates with amoxicillin susceptible MICs.  Eleven of the patients who failed triple therapy also had post-treatment <span class="Italics">H. pylori</span> isolates with clarithromycin resistant MICs.</p>
<p>In the lansoprazole/clarithromycin/amoxicillin triple-therapy clinical trials, 82.6% (195/236) of the patients that had pretreatment amoxicillin susceptible MICs (&lt; 0.25 µg/mL) were eradicated of <span class="Italics">H. pylori</span>.  Of those with pretreatment amoxicillin MICs of &gt; 0.25 µg/mL, three of six had the <span class="Italics">H. pylori</span> eradicated.  A total of 12.8% (22/172) of the patients failed the 10- and 14-day triple-therapy regimens.  Post-treatment susceptibility results were not obtained on 11 of the patients who failed therapy.  Nine of the 11 patients with amoxicillin post-treatment MICs that failed the triple-therapy regimen also had clarithromycin resistant <span class="Italics">H. pylori</span> isolates.</p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Bold"><span class="Underline">but their clinical significance is unknown</span></span>.  Clarithromycin exhibits <span class="Italics">in vitro</span> activity against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of clarithromycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="GN69238"></a><a name="section-3.2.7.1"></a><p></p>
<h4>Aerobic Gram-positive Microorganisms</h4>
<p class="First"><span class="Italics">Streptococcus agalactiae<br>Streptococci </span>(Groups C, F, G)<br>Viridans group streptococci</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN69272"></a><a name="section-3.2.7.2"></a><p></p>
<h4>Aerobic Gram-negative Microorganisms</h4>
<p class="First"><span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span><br>Legionella pneumophila<br>Pasteurella multocida</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN69306"></a><a name="section-3.2.7.3"></a><p></p>
<h4>Anaerobic Gram-positive Microorganisms</h4>
<p class="First"><span class="Italics">Clostridium perfringens<br>Peptococcus  niger<br>Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN69340"></a><a name="section-3.2.7.4"></a><p></p>
<h4>Anaerobic Gram-negative Microorganisms</h4>
<p class="First"><span class="Italics">Prevotella melaninogenica</span> (formerly <span class="Italics">Bacteriodes melaninogenicus</span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN69376"></a><a name="section-3.2.8"></a><p></p>
<h3>Susceptibility Testing Excluding Mycobacteria and Helicobacter</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="GN69399"></a><a name="section-3.2.8.1"></a><p></p>
<h4>Dilution Techniques</h4>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs).  These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds.  The MICs should be determined using a standardized procedure.  Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of clarithromycin powder.  The MIC values should be interpreted according to the following criteria:</p>
<a name="table_5"></a><table width="100%">
<caption><span>For testing Staphylococcus spp.</span></caption>
<colgroup>
<col width="50%">
<col width="49%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule"><span class="Bold">MIC (µg/mL)</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Interpretation</span></td>
</tr>
<tr>
<td>≤ 2.0</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td>4.0</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule">≥ 8.0</td>
<td class="Botrule" align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<a name="table_6"></a><table width="100%">
<caption><span>For testing Streptococcus spp. including Streptococcus pneumoniae <span class="Sup">a</span></span></caption>
<colgroup>
<col width="50%">
<col width="49%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule"><span class="Bold">MIC (µg/mL)</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Interpretation</span></td>
</tr>
<tr>
<td>≤ 0.25</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td>0.5</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr>
<td>≥ 1.0</td>
<td align="center">Resistant (R)</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="2">a   These interpretive standards are applicable only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood.</td></tr>
</tbody>
</table>
<a name="table_7"></a><table width="100%">
<caption><span>For testing Haemophilus spp.<span class="Sup">b</span></span></caption>
<colgroup>
<col width="50%">
<col width="49%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule"><span class="Bold">MIC (µg/mL)</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Interpretation</span></td>
</tr>
<tr>
<td>≤ 8.0</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td>16.0</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr>
<td>≥ 32.0</td>
<td align="center">Resistant (R)</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="2">b   These interpretive standards are applicable only to broth microdilution susceptibility tests with Haemophilus spp. using Haemophilus Testing Medium (HTM).<span class="Sup">1</span>
</td></tr>
</tbody>
</table>
<a name="table_8"></a><table width="100%">
<colgroup><col width="100%"></colgroup>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule">
<span class="Bold">Note:</span>  When testing <span class="Italics">Streptococcus</span> spp., including <span class="Italics">Streptococcus  pneumoniae</span>, susceptibility and resistance to clarithromycin can be predicted using erythromycin.</td></tr>
<tr class="Last"><td class="Botrule"> </td></tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable.  A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.  This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used.  This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation.  A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.  Standard clarithromycin powder should provide the following MIC values:</p>
<a name="table_9"></a><table width="100%">
<colgroup>
<col width="31%">
<col width="18%">
<col width="50%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule" colspan="2"><span class="Bold">Microorganism</span></td>
<td class="Botrule Toprule"><span class="Bold">MIC (µg/mL)</span></td>
</tr>
<tr>
<td><span class="Italics">S. aureus</span></td>
<td align="center">ATCC 29213</td>
<td>0.12 to 0.5</td>
</tr>
<tr>
<td>
<span class="Italics">S. pneumoniae</span><span class="Sup">c</span>
</td>
<td align="center">ATCC 49619</td>
<td>0.03 to 0.12</td>
</tr>
<tr>
<td>
<span class="Italics">Haemophilus influenzae</span><span class="Sup">d</span>
</td>
<td align="center">ATCC 49247</td>
<td>4 to 16</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="3">c   This quality control range is applicable only to <span class="Italics">S. pneumoniae</span> ATCC 49619 tested by a microdilution procedure using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood.<br>d   This quality control range is applicable only to <span class="Italics">H. influenzae  </span> ATCC 49247 tested by a microdilution procedure using HTM<span class="Sup">1</span>.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN69848"></a><a name="section-3.2.8.2"></a><p></p>
<h4>Diffusion Techniques</h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.  One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations.  This procedure uses paper disks impregnated with 15-µg clarithromycin to test the susceptibility of microorganisms to clarithromycin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 15-µg clarithromycin disk should be interpreted according to the following criteria:</p>
<a name="table_10"></a><table width="100%">
<caption><span>For testing Staphylococcus spp.</span></caption>
<colgroup>
<col width="50%">
<col width="49%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule"><span class="Bold">Zone diameter (mm)</span></td>
<td class="Botrule Toprule"><span class="Bold">Interpretation</span></td>
</tr>
<tr>
<td>≥ 18</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>14 to 17</td>
<td>Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule">≤ 13</td>
<td class="Botrule">Resistant (R)</td>
</tr>
</tbody>
</table>
<a name="table_11"></a><table width="100%">
<caption><span>For testing Streptococcus spp. including Streptococcus pneumoniae<span class="Sup">e</span></span></caption>
<colgroup>
<col width="50%">
<col width="49%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule"><span class="Bold">Zone diameter (mm)</span></td>
<td class="Botrule Toprule"><span class="Bold">Interpretation</span></td>
</tr>
<tr>
<td>≥ 21</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>17 to 20</td>
<td>Intermediate (I)</td>
</tr>
<tr>
<td>≤ 16</td>
<td>Resistant (R)</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="2">e   These zone diameter standards only apply to tests performed using Mueller-Hinton agar supplemented with 5% sheep blood incubated in 5% CO<span class="Sub">2</span>.</td></tr>
</tbody>
</table>
<a name="table_12"></a><table width="100%">
<caption><span>For testing Haemophilus spp.<span class="Sup">f</span></span></caption>
<colgroup><col width="47%"></colgroup>
<colgroup><col width="100*"></colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule"><span class="Bold">Zone diameter (mm)</span></td>
<td class="Botrule Toprule"><span class="Bold">Interpretation</span></td>
</tr>
<tr>
<td>≥ 13</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>11 to 12</td>
<td>Intermediate (I)</td>
</tr>
<tr>
<td>≤ 10</td>
<td>Resistant (R)</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="2">f   These zone diameter standards are applicable only to tests with <span class="Italics">Haemophilus </span> spp. using HTM<span class="Sup">2</span>.</td></tr>
</tbody>
</table>
<a name="table_13"></a><table width="100%">
<colgroup><col width="100%"></colgroup>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule">
<span class="Bold">Note:</span>  When testing <span class="Italics">Streptococcus</span> spp., including <span class="Italics">Streptococcus  pneumoniae</span>, susceptibility and resistance to clarithromycin can be predicted using erythromycin.</td></tr>
<tr class="Last"><td class="Botrule"> </td></tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques.  Interpretation involves correlation of the diameter obtained in the disk test with the MIC for clarithromycin.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures.  For the diffusion technique, the 15-µg clarithromycin disk should provide the following zone diameters in this laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>:</p>
<a name="table_14"></a><table width="100%">
<colgroup>
<col width="27%">
<col width="31%">
<col width="40%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule" colspan="2"><span class="Bold">Microorganism</span></td>
<td class="Botrule Toprule"><span class="Bold">Zone diameter (mm)</span></td>
</tr>
<tr>
<td><span class="Italics">S. aureus</span></td>
<td align="center">ATCC 25923</td>
<td>26 to 32</td>
</tr>
<tr>
<td>
<span class="Italics">S. pneumoniae</span><span class="Sup">g</span>
</td>
<td align="center">ATCC 49619</td>
<td>25 to 31</td>
</tr>
<tr>
<td>
<span class="Italics">Haemophilus influenzae</span><span class="Sup">h</span>
</td>
<td align="center">ATCC 49247</td>
<td>11 to 17</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="3">g   This quality control range is applicable only to tests performed by disk diffusion using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood.<br>h   This quality control limit applies to tests conducted with <span class="Italics">Haemophilus influenzae</span> ATCC 49247 using HTM<span class="Sup">2</span>. </td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN70294"></a><a name="section-3.2.9"></a><p></p>
<h3>
<span class="Italics">In vitro</span> Activity of Clarithromycin against Mycobacteria</h3>
<p class="First">Clarithromycin has demonstrated <span class="Italics">in vitro</span> activity against <span class="Italics">Mycobacterium avium</span> complex (MAC) microorganisms isolated from both AIDS and non-AIDS patients.  While gene probe techniques may be used to distinguish <span class="Italics">M. avium</span> species from <span class="Italics">M. intracellulare</span>, many studies only reported results on <span class="Italics">M. avium</span> complex (MAC) isolates.</p>
<p>Various <span class="Italics">in vitro</span> methodologies employing broth or solid media at different pH's, with and without oleic acid-albumin-dextrose-catalase (OADC), have been used to determine clarithromycin MIC values for mycobacterial species.  In general, MIC values decrease more than 16-fold as the pH of Middlebrook 7H12 broth media increases from 5.0 to 7.4.  At pH 7.4, MIC values determined with Mueller-Hinton agar were 4- to 8-fold higher than those observed with Middlebrook 7H12 media.  Utilization of oleic acid-albumin-dextrose-catalase (OADC) in these assays has been shown to further alter MIC values.</p>
<p>Clarithromycin activity against 80 MAC isolates from AIDS patients and 211 MAC isolates from non-AIDS patients was evaluated using a microdilution method with Middlebrook 7H9 broth.  Results showed an MIC value of ≤ 4.0 µg/mL in 81% and 89% of the AIDS and non-AIDS MAC isolates, respectively.  Twelve percent of the non-AIDS isolates had an MIC value ≤ 0.5 µg/mL.  Clarithromycin was also shown to be active against phagocytized <span class="Italics">M. avium</span> complex (MAC) in mouse and human macrophage cell cultures as well as in the beige mouse <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> model.</p>
<p>Clarithromycin activity was evaluated against <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>  </span> microorganisms.  In one study utilizing the agar dilution method with Middlebrook 7H10 media, 3 of 30 clinical isolates had an MIC of 2.5 µg/mL.  Clarithromycin inhibited all isolates at &gt; 10.0 µg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN70364"></a><a name="section-3.2.10"></a><p></p>
<h3>Susceptibility Testing for <span class="Italics">Mycobacterium avium</span> Complex (MAC)</h3>
<p class="First">The disk diffusion and dilution techniques for susceptibility testing against gram-positive and gram-negative bacteria should not be used for determining clarithromycin MIC values against mycobacteria.  <span class="Italics">In vitro</span> susceptibility testing methods and diagnostic products currently available for determining <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) values against <span class="Italics">Mycobacterium avium</span> complex (MAC) organisms have not been standardized or validated.  Clarithromycin MIC values will vary depending on the susceptibility testing method employed, composition and pH of the media, and the utilization of nutritional supplements.  Breakpoints to determine whether clinical isolates of <span class="Italics">M. avium</span> or <span class="Italics">M. intracellulare</span> are susceptible or resistant to clarithromycin have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN70410"></a><a name="section-3.2.11"></a><p></p>
<h3>Susceptibility Test for <span class="Italics">Helicobacter pylori  </span>
</h3>
<p class="First">The reference methodology for susceptibility testing of <span class="Italics">H. pylori</span> is agar dilution MICs.<span class="Sup">3</span>  One to three microliters of an inoculum equivalent to a No. 2 McFarland standard (1 x 10<span class="Sup">7</span>-1 x 10<span class="Sup">8</span> CFU/mL for <span class="Italics">H. pylori</span>) are inoculated directly onto freshly prepared antimicrobial containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood (&gt; 2-weeks old).  The agar dilution plates are incubated at 35°C in a microaerobic environment produced by a gas generating system suitable for <span class="Italics">Campylobacter</span> species.  After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism.  The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria:</p>
<a name="table_15"></a><table width="100%">
<colgroup>
<col width="57%">
<col width="42%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule"><span class="Bold">Clarithromycin MIC (µg/mL)  <span class="Sup">i</span></span></td>
<td class="Botrule Toprule"><span class="Bold">Interpretation</span></td>
</tr>
<tr>
<td>&lt; 0.25</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>0.5-1.0</td>
<td>Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule">&gt; 2.0</td>
<td class="Botrule">Resistant (R)</td>
</tr>
</tbody>
</table>
<a name="table_16"></a><table width="100%">
<colgroup>
<col width="56%">
<col width="43%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule"><span class="Bold">Amoxicillin MIC (µg/mL)  <span class="Sup">i,j</span></span></td>
<td class="Botrule Toprule"><span class="Bold">Interpretation</span></td>
</tr>
<tr>
<td>&lt; 0.25</td>
<td>Susceptible (S)</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="2">i   These are tentative breakpoints for the agar dilution methodology, and they should not be used to interpret results obtained using alternative methods.<br>j   There were not enough organisms with MICs &gt; 0.25 µg/mL to determine a resistance breakpoint.</td></tr>
</tbody>
</table>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.  Standard clarithromycin and amoxicillin powders should provide the following MIC values:</p>
<a name="table_17"></a><table width="100%">
<colgroup>
<col width="14%">
<col width="17%">
<col width="34%">
<col width="33%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule" colspan="2"><span class="Bold">Microorganisms</span></td>
<td class="Botrule Toprule"><span class="Bold">Antimicrobial Agent</span></td>
<td class="Botrule Toprule"><span class="Bold">MIC (µg/mL)<span class="Sup">k</span></span></td>
</tr>
<tr>
<td><span class="Italics">H. pylori</span></td>
<td>ATCC 43504</td>
<td>Clarithromycin</td>
<td>0.015-0.12 µg/mL</td>
</tr>
<tr>
<td><span class="Italics">H. pylori</span></td>
<td>ATCC 43504</td>
<td>Amoxicillin</td>
<td>0.015-0.12 µg/mL</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4">k   These are quality control ranges for the agar dilution methodology and they should not be used to control test results obtained using alternative methods.</td></tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="GN70701"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">BIAXIN Filmtab (clarithromycin tablets, USP) and BIAXIN Granules (clarithromycin for oral suspension, USP) are indicated for the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions as listed below:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="GN70725"></a><a name="section-4.1"></a><p></p>
<h2>Adults (BIAXIN Filmtab Tablets and Granules for Oral Suspension)</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> due to <span class="Italics">Streptococcus pyogenes</span> (The usual drug of choice in the treatment and prevention of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> and the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> is penicillin administered by either the intramuscular or the oral route.  Clarithromycin is generally effective in the eradication of <span class="Italics">S. pyogenes</span> from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available at present).</p>
<p><span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">Acute maxillary sinusitis</span> due to <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis</span>, or <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute bacterial exacerbation of chronic bronchitis</span> due to <span class="Italics">Haemophilus influenzae  </span>, <span class="Italics">Haemophilus parainfluenzae</span>, <span class="Italics">Moraxella catarrhalis</span>, or <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p>Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> due to <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Mycoplasma pneumoniae</span>, <span class="Italics">Streptococcus pneumoniae</span>, or <span class="Italics">Chlamydia pneumoniae </span> (TWAR).</p>
<p>Uncomplicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Staphylococcus aureus  </span>, or <span class="Italics">Streptococcus pyogenes  </span> (<span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span> usually require surgical drainage).</p>
<p>Disseminated <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span> due to <span class="Italics">Mycobacterium avium</span>, or <span class="Italics">Mycobacterium intracellulare  </span></p>
<p>BIAXIN (clarithromycin) Filmtab tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active or five-year history of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>) to eradicate <span class="Italics">H. pylori</span>.</p>
<p>BIAXIN Filmtab tablets in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> associated with <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy.  Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting.</p>
<p>In patients who fail therapy, susceptibility testing should be done if possible.  If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended.  (For information on development of resistance see <span class="Bold">Microbiology</span> section.)  The eradication of <span class="Italics">H. pylori</span> has been demonstrated to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN70862"></a><a name="section-4.2"></a><p></p>
<h2>Children (BIAXIN Filmtab Tablets and Granules for Oral Suspension)</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> due to <span class="Italics">Streptococcus pyogenes</span>.</p>
<p>Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> due to <span class="Italics">Mycoplasma pneumoniae</span>, <span class="Italics">Streptococcus pneumoniae</span>, or <span class="Italics">Chlamydia pneumoniae</span> (TWAR)</p>
<p><span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">Acute maxillary sinusitis</span> due to <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis</span>, or <span class="Italics">Streptococcus pneumoniae </span></p>
<p>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> due to <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis</span>, or <span class="Italics">Streptococcus pneumoniae </span></p>
<p><span class="Bold">NOTE:  </span>  For information on <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, see <span class="Bold">CLINICAL STUDIES - <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></span>.</p>
<p>Uncomplicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Staphylococcus aureus</span>, or <span class="Italics">Streptococcus pyogenes </span>(<span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span> usually require surgical drainage.)</p>
<p>Disseminated <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span> due to <span class="Italics">Mycobacterium avium</span>, or <span class="Italics">Mycobacterium intracellulare </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN70967"></a><a name="section-4.3"></a><p></p>
<h2>Adults (BIAXIN XL Filmtab Tablets)</h2>
<p class="First">BIAXIN XL Filmtab (clarithromycin extended-release tablets) are indicated for the treatment of adults with mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below:</p>
<p><span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">Acute maxillary sinusitis</span> due to <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis</span>, or <span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute bacterial exacerbation of chronic bronchitis</span> due to <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Haemophilus parainfluenzae</span>, <span class="Italics">Moraxella catarrhalis</span>, or <span class="Italics">Streptococcus pneumoniae</span></p>
<p>Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> due to <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Haemophilus parainfluenzae</span>, <span class="Italics">Moraxella catarrhalis</span>, <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Chlamydia pneumoniae</span> (TWAR), or <span class="Italics">Mycoplasma pneumoniae</span></p>
<p><span class="Bold">THE EFFICACY AND SAFETY OF BIAXIN XL IN TREATING OTHER <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> FOR WHICH OTHER FORMULATIONS OF BIAXIN ARE APPROVED HAVE NOT BEEN ESTABLISHED.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71057"></a><a name="section-4.4"></a><p></p>
<h2>Prophylaxis</h2>
<p class="First">BIAXIN Filmtab tablets and BIAXIN Granules for oral suspension are indicated for the prevention of disseminated <span class="Italics">Mycobacterium avium</span> complex (MAC) disease in patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of BIAXIN and other antibacterial drugs, BIAXIN should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="GN71092"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Clarithromycin is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to clarithromycin or any of its excipients, erythromycin, or any of the macrolide antibiotics.</p>
<p>Clarithromycin is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction associated with prior use of clarithromycin.</p>
<p>Concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, and ergotamine or dihydroergotamine (see <span class="Bold">Drug Interactions</span>).  There have been post-marketing reports of drug interactions when clarithromycin and/or erythromycin are coadministered with cisapride, pimozide, astemizole, or terfenadine resulting in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> (QT prolongation, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin.  Fatalities have been reported.</p>
<p>Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>Clarithromycin should not be given to patients with history of QT prolongation or ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, including <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span></span>.</p>
<p>Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins), lovastatin or simvastatin, due to the risk of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Treatment with these agents should be discontinued during clarithromycin treatment (<span class="Bold">see WARNINGS</span>).</p>
<p>For information about contraindications of other drugs indicated in combination with BIAXIN, refer to the <span class="Bold">CONTRAINDICATIONS  </span> section of their package inserts.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="GN71132"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s35619424"></a><a name="section-6.1"></a><p></p>
<h2>Use In Pregnancy</h2>
<p class="First"><span class="Bold">CLARITHROMYCIN SHOULD NOT BE USED IN PREGNANT WOMEN EXCEPT IN CLINICAL CIRCUMSTANCES WHERE NO ALTERNATIVE THERAPY IS APPROPRIATE.  IF PREGNANCY OCCURS WHILE TAKING THIS DRUG, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS.  CLARITHROMYCIN HAS DEMONSTRATED ADVERSE EFFECTS OF PREGNANCY OUTCOME AND/OR EMBRYO-FETAL DEVELOPMENT IN MONKEYS, RATS, MICE, AND RABBITS AT DOSES THAT PRODUCED PLASMA LEVELS 2 TO 17 TIMES THE SERUM LEVELS ACHIEVED IN HUMANS TREATED AT THE MAXIMUM RECOMMENDED HUMAN DOSES.  (See PRECAUTIONS - </span><span class="Italics"><span class="Bold">Pregnancy</span></span><span class="Bold">.)</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s14365924"></a><a name="section-6.2"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, has been reported with clarithromycin. This hepatic dysfunction may be severe and is usually reversible. In some instances, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications. Discontinue clarithromycin immediately if signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36126724"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Serious adverse reactions have been reported in patients taking clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with simvastatin, lovastatin, and atorvastatin; and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) (see <span class="Bold">CONTRAINDICATIONS</span> and <span class="Bold">PRECAUTIONS </span><span class="Bold">–</span><span class="Bold"> Drug Interactions</span>).</p>
<p>Life-threatening and fatal drug interactions have been reported in patients treated with clarithromycin and colchicine. Clarithromycin is a strong CYP3A4 inhibitor and this interaction may occur while using both drugs at their recommended doses. If co-administration of clarithromycin and colchicine is necessary in patients with normal renal and hepatic function, the dose of colchicine should be reduced. Patients should be monitored for clinical symptoms of colchicine toxicity. Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (see <span class="Bold">CONTRAINDICATIONS</span> and <span class="Bold">PRECAUTIONS – Drug Interactions</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36130524"></a><a name="section-6.4"></a><p></p>
<h2>
<span class="Italics">Clostridium difficile</span> Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including BIAXIN, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of<span class="Italics"> C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p> If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p>For information about warnings of other drugs indicated in combination with BIAXIN, refer to the <span class="Bold">WARNINGS</span> section of their package inserts.</p>
<p>Due to the risk for QT prolongation clarithromycin should be used with caution in patients with a medical condition associated with an increased tendency toward QT prolongation and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span></span>. </p>
<p>In the event of severe acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS), and Henoch-Schonlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s37652724"></a><a name="section-6.4.1"></a><p></p>
<h3>Oral Hypoglycemic Agents/Insulin</h3>
<p class="First">The concomitant use of clarithromycin and oral hypoglycemic agents and/or insulin can result in significant <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypolgycemia when used concomitantly. Careful monitoring of glucose is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s379061224"></a><a name="section-6.4.2"></a><p></p>
<h3>Oral Anticoagulants</h3>
<p class="First">There is a risk of serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and significant elevations in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when clarithromycin is co-administered with warfarin. INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times should be frequently monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37653824"></a><a name="section-6.4.3"></a><p></p>
<h3>HMG-CoA Reductase Inhibitors</h3>
<p class="First">Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see <span class="Bold">CONTRAINDICATIONS</span>). As with other macrolides, clarithromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors.  Rare reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients taking these drugs concomitantly. Patients should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.  </p>
<p>Rare reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have also been reported in patients taking atorvastatin or rosuvastatin concomitantly with clarithromycin.  When used with clarithromycin, atorvastatin or rosuvastatin should be administered in the lowest possible doses.  Adjustment of the statin dose or use of a statin that is not dependent on CYP3A metabolism (e.g.fluvastatin or pravastatin) should be considered.  </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="GN71217"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="GN71237"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing BIAXIN in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Clarithromycin is principally excreted via the liver and kidney.  Clarithromycin may be administered without dosage adjustment to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and normal renal function.  However, in the presence of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with or without coexisting <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, decreased dosage or prolonged dosing intervals may be appropriate.</p>
<p>Clarithromycin in combination with ranitidine bismuth citrate therapy is not recommended in patients with creatinine clearance less than 25 mL/min.  (See <span class="Bold">DOSAGE AND ADMINISTRATION</span>.)</p>
<p>Clarithromycin in combination with ranitidine bismuth citrate should not be used in patients with a history of acute <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>.</p>
<p>Exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and new onset of symptoms of <span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">myasthenic syndrome</span> has been reported in patients receiving clarithromycin therapy.</p>
<p>For information about precautions of other drugs indicated in combination with BIAXIN, refer to the <span class="Bold">PRECAUTIONS </span> section of their package inserts.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="GN71286"></a><a name="section-7.2"></a><p></p>
<h2>Information to Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including BIAXIN should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When BIAXIN is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by BIAXIN or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.  Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic.  If this occurs, patients should contact their physician as soon as possible.</p>
<p>BIAXIN may interact with some drugs; therefore patients should be advised to report to their doctor the use of any other medications.</p>
<p>BIAXIN tablets and oral suspension can be taken with or without food and can be taken with milk; however, BIAXIN XL tablets should be taken with food.  Do <span class="Bold">NOT  </span> refrigerate the suspension.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="GN71325"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations.  Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range.  In two studies in which theophylline was administered with clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg q12h clarithromycin), the steady-state levels of C<span class="Sub">max</span>, C<span class="Sub">min</span>, and the area under the serum concentration time curve (AUC) of theophylline increased about 20%.</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have been observed in patients receiving concurrent verapamil, belonging to the calcium channel blockers drug class.</p>
<p>Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine.  Blood level monitoring of carbamazepine may be considered.</p>
<p>When clarithromycin and terfenadine were coadministered, plasma concentrations of the active acid metabolite of terfenadine were threefold higher, on average, than the values observed when terfenadine was administered alone.  The pharmacokinetics of clarithromycin and the 14-OH-clarithromycin were not significantly affected by coadministration of terfenadine once clarithromycin reached steady-state conditions.  Concomitant administration of clarithromycin with terfenadine is contraindicated.  (See <span class="Bold">CONTRAINDICATIONS</span>.)</p>
<p>Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult subjects.  The steady-state plasma concentrations of omeprazole were increased (C<span class="Sub">max</span>, AUC<span class="Sub">0-24</span>, and t<span class="Sub">½</span> increases of 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin.  The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when coadministered with clarithromycin.</p>
<p>Coadministration of clarithromycin with ranitidine bismuth citrate resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14-hydroxy-clarithromycin plasma concentrations (31%).  These effects are clinically insignificant.</p>
<p>Simultaneous oral administration of BIAXIN tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Following administration of clarithromycin 500 mg tablets twice daily with zidovudine 100 mg every 4 hours, the steady-state zidovudine AUC decreased 12% compared to administration of zidovudine alone (n=4). Individual values ranged from a decrease of 34% to an increase of 14%. When clarithromycin tablets were administered two to four hours prior to zidovudine, the steady-state zidovudine C<span class="Sub">max</span> increased 100% whereas the AUC was unaffected (n=24). Administration of clarithromycin and zidovudine should be separated by at least two hours. The impact of co-administration of clarithromycin extended-release tablets and zidovudine has not been evaluated.</p>
<p>Simultaneous administration of BIAXIN tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.</p>
<p>Following administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers, the steady-state clarithromycin C<span class="Sub">min</span> and AUC increased 33% and 18%, respectively.  Steady-state concentrations of 14-OH clarithromycin were not significantly affected by concomitant administration of fluconazole. No dosage adjustment of clarithromycin is necessary when co-administered with fluconazole.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="s13869124"></a><a name="section-7.3.1"></a><p></p>
<h3>Ritonavir</h3>
<p class="First">Concomitant administration of clarithromycin and ritonavir (n = 22) resulted in a 77% increase in clarithromycin AUC and a 100% decrease in the AUC of 14-OH clarithromycin.  Clarithromycin may be administered without dosage adjustment to patients with normal renal function taking ritonavir. Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with ritonavir, alternative antibacterial therapy should be considered for indications other than <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Mycobacterium avium</span> complex (see <span class="Bold">PRECAUTIONS – Drug </span><span class="Bold">Interactions</span>). Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</p>
<p>Spontaneous reports in the post-marketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants.  <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously.</p>
<p>Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are co-administered, inhibition of Pgp by clarithromycin may lead to increased exposure of digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in post-marketing surveillance.  Some patients have shown clinical signs consistent with <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>, including potentially fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range.</p>
<p>Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.</p>
<p>Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.</p>
<p>The following are examples of some clinically significant CYP3A based drug interactions.  Interactions with other drugs metabolized by the CYP3A isoform are also possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71426"></a><a name="section-7.3.2"></a><p></p>
<h3>Carbamazepine and Terfenadine</h3>
<p class="First">Increased serum concentrations of carbamazepine and the active acid metabolite of terfenadine were observed in clinical trials with clarithromycin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35884624"></a><a name="section-7.3.3"></a><p></p>
<h3>Colchicine</h3>
<p class="First">Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When a single dose of colchicine 0.6 mg was administered with clarithromycin 250 mg BID for 7 days, the colchicine C<span class="Sub">max</span> increased 197% and the AUC<span class="Sub">0-∞</span> increased 239% compared to administration of colchicine alone. The dose of colchicine should be reduced when co-administered with clarithromycin in patients with normal renal and hepatic function. Concomitant use of clarithromycin and colchicine is contraindicated in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (See <span class="Bold">WARNINGS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71451"></a><a name="section-7.3.4"></a><p></p>
<h3>Efavirenz, Nevirapine, Rifampicin, Rifabutin, and Rifapentine</h3>
<p class="First">Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of clarithromycin, thus decreasing plasma concentrations of clarithromycin, while increasing those of 14-OH-clarithromycin. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers. Alternative antibacterial treatment should be considered when treating patients receiving inducers of CYP3A.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71476"></a><a name="section-7.3.5"></a><p></p>
<h3>Sildenafil, Tadalafil, and Vardenafil</h3>
<p class="First">Each of these phosphodiesterase inhibitors is primarily metabolized by CYP3A, and CYP3A will be inhibited by concomitant administration of clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil, or vardenafil will result in increased exposure of these phosphodiesterase inhibitors. Co-administration of these phosphodiesterase inhibitors with clarithromycin is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71504"></a><a name="section-7.3.6"></a><p></p>
<h3>Tolterodine</h3>
<p class="First">The primary route of metabolism for tolterodine is via CYP2D6. However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when co-administered with clarithromycin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71529"></a><a name="section-7.3.7"></a><p></p>
<h3>Triazolobenzodiazepines (e.g., alprazolam, midazolam, triazolam)</h3>
<p class="First">When a single dose of midazolam was co-administered with clarithromycin tablets (500 mg twice daily for 7 days), midazolam AUC increased 174% after intravenous administration of midazolam and 600% after oral administration. When oral midazolam is co-administered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated. Caution and appropriate dose adjustments should be considered when triazolam or alprazolam is co-administered with clarithromycin. For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely. </p>
<p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g., <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71557"></a><a name="section-7.3.8"></a><p></p>
<h3>Atazanavir</h3>
<p class="First">Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Following administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily), the clarithromycin AUC increased 94%, the 14-OH clarithromycin AUC decreased 70% and the atazanavir AUC increased 28%. When clarithromycin is co-administered with atazanavir, the dose of clarithromycin should be decreased by 50%. Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with atazanavir, alternative antibacterial therapy should be considered for indications other than <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Mycobacterium avium</span> complex (see <span class="Bold">PRECAUTIONS – Drug Interactions</span>). Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71585"></a><a name="section-7.3.9"></a><p></p>
<h3>Itraconazole</h3>
<p class="First">Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly. Clarithromycin may increase the plasma concentrations of itraconazole, while itraconazole may increase the plasma concentrations of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71610"></a><a name="section-7.3.10"></a><p></p>
<h3>Saquinavir</h3>
<p class="First">Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction. Following administration of clarithromycin (500 mg bid) and saquinavir (soft gelatin capsules, 1200 mg tid) to 12 healthy volunteers, the steady-state saquinavir AUC and C<span class="Sub">max</span> increased 177% and 187% respectively compared to administration of saquinavir alone. Clarithromycin AUC and C<span class="Sub">max</span> increased 45% and 39% respectively, whereas the 14–OH clarithromycin AUC and C<span class="Sub">max</span> decreased 24% and 34% respectively, compared to administration with clarithromycin alone. No dose adjustment of clarithromycin is necessary when clarithromycin is co-administered with saquinavir in patients with normal renal function. When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (refer to interaction between clarithromycin and ritonavir) (see <span class="Bold">PRECAUTIONS — Drug Interactions</span>).</p>
<p>The following CYP3A based drug interactions have been observed with erythromycin products and/or with clarithromycin in post-marketing experience:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71647"></a><a name="section-7.3.11"></a><p></p>
<h3>Antiarrhythmics</h3>
<p class="First">There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> occurring with concurrent use of clarithromycin and quinidine or disopyramide.  Electrocardiograms should be monitored for QTc prolongation during coadministration of clarithromycin with these drugs.  Serum concentrations of these medications should also be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71673"></a><a name="section-7.3.12"></a><p></p>
<h3>Ergotamine/Dihydroergotamine</h3>
<p class="First">Post-marketing reports indicate that coadministration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues including the central nervous system.  Concomitant administration of clarithromycin with ergotamine or dihydroergotamine is contraindicated (see <span class="Bold">CONTRAINDICATIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71703"></a><a name="section-7.3.13"></a><p></p>
<h3>Triazolobenziodidiazepines (Such as Triazolam and Alprazolam) and Related Benzodiazepines (Such as Midazolam)</h3>
<p class="First">Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.  There have been post-marketing reports of drug interactions and CNS effects (e.g., <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) with the concomitant use of clarithromycin and triazolam.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71755"></a><a name="section-7.3.14"></a><p></p>
<h3>Sildenafil (Viagra)</h3>
<p class="First">Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil.  A similar interaction may occur with clarithromycin; reduction of sildenafil dosage should be considered.  (See Viagra package insert.)</p>
<p>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, bromocriptine and vinblastine.</p>
<p>Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see <span class="Bold">CONTRAINDICATIONS</span>.)</p>
<p>In addition, there have been reports of interactions of erythromycin or clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="GN71796"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The following <span class="Italics">in vitro  </span> mutagenicity tests have been conducted with clarithromycin:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>/Mammalian Microsomes Test</p>
<p>Bacterial Induced Mutation Frequency Test</p>
<p><span class="Italics">In Vitro</span> Chromosome Aberration Test</p>
<p>Rat Hepatocyte DNA Synthesis Assay</p>
<p>Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Assay</p>
<p>Mouse Dominant Lethal Study</p>
<p>Mouse Micronucleus Test</p>
<p>All tests had negative results except the <span class="Italics">In Vitro  </span> Chromosome Aberration Test which was weakly positive in one test and negative in another.</p>
<p>In addition, a Bacterial Reverse-Mutation Test (Ames Test) has been performed on clarithromycin metabolites with negative results.</p>
<p>Fertility and reproduction studies have shown that daily doses of up to 160 mg/kg/day (1.3 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>) to male and female rats caused no adverse effects on the estrous cycle, fertility, parturition, or number and viability of offspring.  Plasma levels in rats after 150 mg/kg/day were 2 times the human serum levels.</p>
<p>In the 150 mg/kg/day monkey studies, plasma levels were 3 times the human serum levels.  When given orally at 150 mg/kg/day (2.4 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>), clarithromycin was shown to produce embryonic loss in monkeys.  This effect has been attributed to marked maternal toxicity of the drug at this high dose.</p>
<p>In rabbits, <span class="Italics">in utero</span> fetal loss occurred at an intravenous dose of 33 mg/m<span class="Sup">2</span>, which is 17 times less than the maximum proposed human oral daily dose of 618 mg/m<span class="Sup">2</span>.</p>
<p>Long-term studies in animals have not been performed to evaluate the carcinogenic potential of clarithromycin.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="GN71893"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="GN71915"></a><a name="section-7.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="GN71938"></a><a name="section-7.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Four <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies in rats (three with oral doses and one with intravenous doses up to 160 mg/kg/day administered during the period of major organogenesis) and two in rabbits at oral doses up to 125 mg/kg/day (approximately 2 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>) or intravenous doses of 30 mg/kg/day administered during gestation days 6 to 18 failed to demonstrate any <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> from clarithromycin.  Two additional oral studies in a different rat <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> at similar doses and similar conditions demonstrated a low incidence of cardiovascular anomalies at doses of 150 mg/kg/day administered during gestation days 6 to 15.  Plasma levels after 150 mg/kg/day were 2 times the human serum levels.  Four studies in mice revealed a variable incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> following oral doses of 1000 mg/kg/day (2 and 4 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>, respectively) during gestation days 6 to 15.  <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">Cleft palate</span> was also seen at 500 mg/kg/day.  The 1000 mg/kg/day exposure resulted in plasma levels 17 times the human serum levels.  In monkeys, an oral dose of 70 mg/kg/day (an approximate equidose of the recommended maximum human dose based on mg/m<span class="Sup">2</span>) produced <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> at plasma levels that were 2 times the human serum levels.</p>
<p>There are no adequate and well-controlled studies in pregnant women.  Clarithromycin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  (See <span class="Bold">WARNINGS</span>.)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="GN71982"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether clarithromycin is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when clarithromycin is administered to a nursing woman.  It is known that clarithromycin is excreted in the milk of lactating animals and that other drugs of this class are excreted in human milk.  Preweaned rats, exposed indirectly via consumption of milk from dams treated with 150 mg/kg/day for 3 weeks, were not adversely affected, despite data indicating higher drug levels in milk than in plasma.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="GN72008"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of clarithromycin in pediatric patients under 6 months of age have not been established.  The safety of clarithromycin has not been studied in MAC patients under the age of 20 months.  Neonatal and juvenile animals tolerated clarithromycin in a manner similar to adult animals.  Young animals were slightly more intolerant to acute overdosage and to subtle reductions in erythrocytes, platelets and leukocytes but were less sensitive to toxicity in the liver, kidney, thymus, and genitalia.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="GN72034"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In a steady-state study in which healthy elderly subjects (age 65 to 81 years old) were given 500 mg every 12 hours, the maximum serum concentrations and area under the curves of clarithromycin and 14-OH clarithromycin were increased compared to those achieved in healthy young adults.  These changes in pharmacokinetics parallel known age-related decreases in renal function.  In clinical trials, elderly patients did not have an increased incidence of adverse events when compared to younger patients.  Dosage adjustment should be considered in elderly patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (See <span class="Bold">WARNINGS</span> and <span class="Bold">PRECAUTIONS</span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="GN72070"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The majority of side effects observed in clinical trials were of a mild and transient nature.  Fewer than 3% of adult patients without <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span> and fewer than 2% of pediatric patients without <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span> discontinued therapy because of drug-related side effects.  Fewer than 2% of adult patients taking BIAXIN XL tablets discontinued therapy because of drug-related side effects.</p>
<p>The most frequently reported events in adults taking BIAXIN tablets (clarithromycin tablets, USP) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (3%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%), abnormal taste (3%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (2%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (2%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2%).  In pediatric patients, the most frequently reported events were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (6%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (3%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2%).  Most of these events were described as mild or moderate in severity.  Of the reported adverse events, only 1% was described as severe.</p>
<p>The most frequently reported events in adults taking BIAXIN XL (Clarithromycin extended-release tablets) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6%), abnormal taste (7%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%).  Most of these events were described as mild or moderate in severity.  Of the reported adverse events, less than 1% were described as severe.</p>
<p>In the <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">acute exacerbation of chronic bronchitis</span> and <span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">acute maxillary sinusitis</span> studies overall gastrointestinal adverse events were reported by a similar proportion of patients taking either BIAXIN tablets or BIAXIN XL tablets; however, patients taking BIAXIN XL tablets reported significantly less severe <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> compared to patients taking BIAXIN tablets.  In addition, patients taking BIAXIN XL tablets had significantly fewer premature discontinuations for drug-related gastrointestinal or abnormal taste adverse events compared to BIAXIN tablets.</p>
<p>In community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> studies conducted in adults comparing clarithromycin to erythromycin base or erythromycin stearate, there were fewer adverse events involving the digestive system in clarithromycin-treated patients compared to erythromycin-treated patients (13% vs 32%; p &lt; 0.01).  Twenty percent of erythromycin-treated patients discontinued therapy due to adverse events compared to 4% of clarithromycin-treated patients.</p>
<p>In two  U.S. studies of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> comparing clarithromycin to amoxicillin/potassium clavulanate in pediatric patients, there were fewer adverse events involving the digestive system in clarithromycin-treated patients compared to amoxicillin/potassium clavulanate-treated patients (21% vs. 40%, p &lt; 0.001).  One-third as many clarithromycin-treated patients reported <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> as did amoxicillin/potassium clavulanate-treated patients.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="GN72109"></a><a name="section-8.1"></a><p></p>
<h2>Post-Marketing Experience</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> ranging from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span> to rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS), Henoch-Schonlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span>  and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have occurred.  Other spontaneously reported adverse events include <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">tongue discoloration</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.  There have been reports of <span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">tooth discoloration</span> in patients treated with BIAXIN.  <span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">Tooth discoloration</span> is usually reversible with professional dental cleaning.  There have been isolated reports of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, which is usually reversible, occurring chiefly in elderly women.  Reports of alterations of the sense of smell including <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">smell loss</span>, usually in conjunction with <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> or <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, have also been reported.</p>
<p>Transient CNS events including <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, behavioral changes, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional states</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> behavior, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> have been reported during post-marketing surveillance.  Events usually resolve with discontinuation of the drug.</p>
<p>Adverse reactions related to hepatic dysfunction have been reported in postmarketing experience with clarithromycin. (See <span class="Bold">WARNINGS – Hepatotoxicity</span>).</p>
<p>There have been rare reports of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, some of which have occurred in patients taking oral hypoglycemic agents or insulin.</p>
<p>There have been post-marketing reports of BIAXIN XL tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> with shortened GI transit times.</p>
<p>As with other macrolides, clarithromycin has been associated with QT prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>.</p>
<p>There have been reports of interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> coincident with clarithromycin use.</p>
<p>There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> have been reported in some such patients.  (See <span class="Bold">WARNINGS</span> and <span class="Bold">PRECAUTIONS</span>.)</p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> coincident with clarithromycin use. In some reports, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN72164"></a><a name="section-8.2"></a><p></p>
<h2>Changes in Laboratory Values</h2>
<p class="First">Changes in laboratory values with possible clinical significance were as follows:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="GN72188"></a><a name="section-8.2.1"></a><p></p>
<h3>Hepatic</h3>
<p class="First">Elevated SGPT (ALT) &lt; 1%; <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST) &lt; 1%; GGT &lt; 1%; alkaline phosphatase &lt; 1%; LDH &lt; 1%; total bilirubin &lt; 1%</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN72214"></a><a name="section-8.2.2"></a><p></p>
<h3>Hematologic</h3>
<p class="First">Decreased WBC &lt; 1%; elevated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time 1%</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN72240"></a><a name="section-8.2.3"></a><p></p>
<h3>Renal</h3>
<p class="First">Elevated BUN 4%; elevated serum creatinine &lt; 1%</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN72265"></a><a name="section-8.2.4"></a><p></p>
<p class="First">GGT, alkaline phosphatase, and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time data are from adult studies only.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="GN72292"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage of clarithromycin can cause <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures.  As with other macrolides, clarithromycin serum concentrations are not expected to be appreciably affected by hemodialysis or peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="GN72321"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">BIAXIN Filmtab (clarithromycin tablets, USP) and BIAXIN Granules (clarithromycin for oral suspension, USP) may be given with or without food.  BIAXIN XL Filmtab (clarithromycin extended-release tablets) should be taken with food.  BIAXIN XL tablets should be swallowed whole and not chewed, broken or crushed.</p>
<p>Clarithromycin may be administered without dosage adjustment in the presence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> if there is normal renal function.  In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>  (CL<span class="Sub">CR</span> &lt; 30 mL/min), the dose of clarithromycin should be reduced by 50%.  However, when patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are taking clarithromycin concomitantly with atazanavir or ritonavir, the dose of clarithromycin should be reduced by 50% or 75% for patients with CL<span class="Sub">CR</span> of 30 to 60 mL/min or &lt; 30 mL/min, respectively.  </p>
<a name="table_18"></a><table width="100%">
<caption><span>ADULT DOSAGE GUIDELINES</span></caption>
<colgroup>
<col align="left" width="280*">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="12%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Toprule" align="left"> </td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">BIAXIN Tablets</span></td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">BIAXIN XL Tablets</span></td>
</tr>
<tr valign="top">
<td class="Botrule" align="center"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Botrule" align="center"><span class="Bold">Dosage<br>(q12h)</span></td>
<td class="Botrule"><span class="Bold">Duration<br>(days)</span></td>
<td class="Botrule" align="center"><span class="Bold">Dosage<br>(q24h)</span></td>
<td class="Botrule" align="center"><span class="Bold">Duration<br>(days)</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> due to</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td align="left">     <span class="Italics">S. pyogenes</span>
</td>
<td align="center">250 mg</td>
<td align="center">10</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">Acute maxillary sinusitis</span> due to</td>
<td align="center">500 mg</td>
<td align="center">14</td>
<td align="center">2 x 500 mg</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">     <span class="Italics">H. influenzae</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td align="left">     <span class="Italics">M. catarrhalis</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td align="left">     <span class="Italics">S. pneumoniae</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Acute exacerbation of chronic bronchitis</span> due to</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td align="left">     <span class="Italics">H. influenzae</span>
</td>
<td align="center">500 mg</td>
<td align="center">7-14</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">     <span class="Italics">H. parainfluenzae</span>
</td>
<td align="center">500 mg</td>
<td align="center">7</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">     <span class="Italics">M. catarrhalis</span>
</td>
<td align="center">250 mg</td>
<td align="center">7-14</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">     <span class="Italics">S. pneumoniae</span>
</td>
<td align="center">250 mg</td>
<td align="center">7-14</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> due to</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td align="left">     <span class="Italics">H. influenzae</span>
</td>
<td align="center">250 mg</td>
<td align="center">7</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">     <span class="Italics">H. parainfluenzae</span>
</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">     <span class="Italics">M. catarrhalis </span>
</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">     <span class="Italics">S. pneumoniae</span>
</td>
<td align="center">250 mg</td>
<td align="center">7-14</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">     <span class="Italics">C. pneumoniae</span>
</td>
<td align="center">250 mg</td>
<td align="center">7-14</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">     <span class="Italics">M. pneumoniae</span>
</td>
<td align="center">250 mg</td>
<td align="center">7-14</td>
<td align="center">2 x 500 mg</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Uncomplicated skin and skin structure</td>
<td align="center">250 mg</td>
<td align="center">7-14</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left">     <span class="Italics">S. aureus</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left">     <span class="Italics">S. pyogenes</span>
</td>
<td class="Botrule" align="center"> </td>
<td class="Botrule" align="center"> </td>
<td class="Botrule" align="center"> </td>
<td class="Botrule" align="center"> </td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="GN72927"></a><a name="section-10.1"></a><p></p>
<h2>
<span class="Italics">H. pylori </span>Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="GN72952"></a><a name="section-10.1.1"></a><p></p>
<h3>Triple therapy:  BIAXIN/lansoprazole/amoxicillin</h3>
<p class="First">The recommended adult dose is 500 mg BIAXIN, 30 mg lansoprazole, and 1 gram amoxicillin, all given twice daily (q12h) for 10 or 14 days.  (See <span class="Bold">INDICATIONS AND USAGE </span>and<span class="Bold"> CLINICAL STUDIES</span> sections.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN72986"></a><a name="section-10.1.2"></a><p></p>
<h3>Triple therapy:  BIAXIN/omeprazole/amoxicillin</h3>
<p class="First">The recommended adult dose is 500 mg BIAXIN, 20 mg omeprazole, and 1 gram amoxicillin, all given twice daily (q12h) for 10 days.  (See <span class="Bold">INDICATIONS AND USAGE</span> and <span class="Bold">CLINICAL STUDIES</span> sections.)  In patients with an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> present at the time of initiation of therapy, an additional 18 days of omeprazole 20 mg once daily is recommended for <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> healing and symptom relief.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73018"></a><a name="section-10.1.3"></a><p></p>
<h3>Dual therapy:  BIAXIN/omeprazole</h3>
<p class="First">The recommended adult dose is 500 mg BIAXIN given three times daily (q8h) and 40 mg omeprazole given once daily (qAM) for 14 days.  (See <span class="Bold">INDICATIONS AND USAGE</span> and <span class="Bold">CLINICAL STUDIES</span> sections.)  An additional 14 days of omeprazole 20 mg once daily is recommended for <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> healing and symptom relief.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73051"></a><a name="section-10.1.4"></a><p></p>
<h3>Dual therapy:  BIAXIN/ranitidine bismuth citrate</h3>
<p class="First">The recommended adult dose is 500 mg BIAXIN given twice daily (q12h) or three times daily (q8h) and 400 mg ranitidine bismuth citrate given twice daily (q12h) for 14 days.  An additional 14 days of 400 mg twice daily is recommended for <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> healing and symptom relief.  BIAXIN and ranitidine bismuth citrate combination therapy is not recommended in patients with creatinine clearance less than 25 mL/min.  (See <span class="Bold">INDICATIONS AND USAGE</span> and <span class="Bold">CLINICAL STUDIES</span> sections.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73084"></a><a name="section-10.1.5"></a><p></p>
<h3>Children</h3>
<p class="First">The usual recommended daily dosage is 15 mg/kg/day divided q12h for 10 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73111"></a><a name="section-10.2"></a><p></p>
<a name="table_19"></a><table width="100%">
<caption><span>PEDIATRIC DOSAGE GUIDELINES</span></caption>
<colgroup>
<col width="6%">
<col width="8%">
<col width="28%">
<col width="28%">
<col width="27%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom"><td class="Toprule" align="center" colspan="5"><span class="Bold">Based on Body Weight</span></td></tr>
<tr valign="bottom"><td align="center" colspan="5"><span class="Bold">Dosing Calculated on 7.5 mg/kg q12h</span></td></tr>
<tr valign="bottom">
<td align="center" colspan="2"><span class="Bold">Weight</span></td>
<td align="center"><span class="Bold">Dose</span></td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr valign="top">
<td class="Botrule" align="center"><span class="Bold">Kg</span></td>
<td class="Botrule" align="center"><span class="Bold">lbs</span></td>
<td class="Botrule" align="center">(q12h)</td>
<td class="Botrule" align="center"><span class="Bold">125 mg/5 mL</span></td>
<td class="Botrule" align="center"><span class="Bold">250 mg/5 mL</span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">9<br>17<br>25<br>33</td>
<td class="Botrule" align="center">20<br>37<br>55<br>73</td>
<td class="Botrule" align="center">62.5 mg<br>125 mg<br>187.5 mg<br>250 mg</td>
<td class="Botrule" align="center">2.5 mL q12h<br>   5 mL q12h<br>7.5 mL q12h<br> 10 mL q12h</td>
<td class="Botrule" align="center">1.25 mL q12h<br>2.5 mL q12h<br>3.75 mL q12h<br>5 mL q12h</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73309"></a><a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">Mycobacterial Infections</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73332"></a><a name="section-10.3.1"></a><p></p>
<h3>Prophylaxis</h3>
<p class="First">The recommended dose of BIAXIN for the prevention of disseminated <span class="Italics">Mycobacterium avium</span> disease is 500 mg b.i.d.  In children, the recommended dose is 7.5 mg/kg b.i.d. up to 500 mg b.i.d.  No studies of clarithromycin for MAC prophylaxis have been performed in pediatric populations and the doses recommended for prophylaxis are derived from MAC treatment studies in children.  Dosing recommendations for children are in the table above.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73362"></a><a name="section-10.3.2"></a><p></p>
<h3>Treatment</h3>
<p class="First">Clarithromycin is recommended as the primary agent for the treatment of disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> due to <span class="Italics">Mycobacterium avium</span> complex.  Clarithromycin should be used in combination with other antimycobacterial drugs that have shown <span class="Italics">in vitro</span> activity against MAC or clinical benefit in MAC treatment.  (See <span class="Bold">CLINICAL STUDIES</span>.)  The recommended dose for <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span> in adults is 500 mg b.i.d.  In children, the recommended dose is 7.5 mg/kg b.i.d. up to 500 mg b.i.d.  Dosing recommendations for children are in the table above.</p>
<p>Clarithromycin therapy should continue for life if clinical and mycobacterial improvements are observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73405"></a><a name="section-10.4"></a><p></p>
<h2>Constituting Instructions</h2>
<p class="First">The table below indicates the volume of water to be added when constituting:</p>
<a name="table_20"></a><table width="100%">
<colgroup>
<col width="31%">
<col width="35%">
<col width="33%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule" align="center"><span class="Bold">Total Volume After Constitution</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Clarithromycin Concentration After Constitution</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Amount of Water to be Added*</span></td>
</tr>
<tr>
<td align="center">50 mL</td>
<td align="center">125 mg/5 mL</td>
<td align="center">27 mL</td>
</tr>
<tr>
<td align="center">100 mL</td>
<td align="center">125 mg/5 mL</td>
<td align="center">55 mL</td>
</tr>
<tr>
<td align="center">50 mL</td>
<td align="center">250 mg/5 mL</td>
<td align="center">27 mL</td>
</tr>
<tr>
<td align="center">100 mL</td>
<td align="center">250 mg/5 mL</td>
<td align="center">55 mL</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="3">*   see instructions below.</td></tr>
</tbody>
</table>
<p>Add half the volume of water to the bottle and shake vigorously.  Add the remainder of water to the bottle and shake.</p>
<p>Shake well before each use.  Oversize bottle provides shake space.  Keep tightly closed.  Do not refrigerate.  After mixing, store at 15° to 30°C (59° to 86°F) and use within 14 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="GN73559"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">BIAXIN XL Filmtab (clarithromycin extended-release tablets) are supplied as yellow oval film-coated 500 mg tablets debossed (on one side) with the Abbott logo and a two-letter Abbo-Code designation, KJ in the following packaging sizes:</p>
<p>500 mg tablets:</p>
<a name="iee34fdce-7400-47d8-8db9-748568423960"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 20<br>
</td>
<td>NDC 54868-4191-0<br>
</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack of 14<br>
</td>
<td>NDC 54868-4191-1<br>
</td>
</tr>
</tbody></table>
<p>Store BIAXIN XL tablets at 20° to 25°C (68° to 77°F).  Excursions permitted to 15° to 30°C (59° to 86°F).  [See USP Controlled Room Temperature.]</p>
<p><br></p>
<p>BIAXIN Granules (clarithromycin for oral suspension, USP) is supplied in the following strengths and sizes:</p>
<a name="table_21"></a><table width="100%">
<col width="23%">
<col width="25%">
<col width="25%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Total Volume After Constitution</span></td>
<td><span class="Bold">Clarithromycin Concentration After Constitution</span></td>
<td><span class="Bold">Clarithromycin Contents Per Bottle</span></td>
<td><span class="Bold">NDC</span></td>
</tr>
<tr class="Last">
<td>100 mL</td>
<td>250 mg/5 mL</td>
<td>5000 mg</td>
<td>54868-3384-0</td>
</tr>
</tbody>
</table>
<p>Store BIAXIN granules for oral suspension at controlled room temperature 15° to 30°C (59° to 86°F) in a well-closed container.  Do not refrigerate BIAXIN suspension.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="GN73782"></a><a name="section-12"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73802"></a><a name="section-12.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">Mycobacterial Infections</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73825"></a><a name="section-12.1.1"></a><p></p>
<h3>Prophylaxis</h3>
<p class="First">A randomized, double-blind study (561) compared clarithromycin 500 mg b.i.d. to placebo in patients with CDC-defined AIDS and CD<span class="Sub">4</span> counts &lt; 100 cells/µL.  This study accrued 682 patients from November 1992 to January 1994, with a median CD<span class="Sub">4</span> cell count at study entry of 30 cells/µL.  Median duration of clarithromycin was 10.6 months vs. 8.2 months for placebo.  More patients in the placebo arm than the clarithromycin arm discontinued prematurely from the study (75.6% and 67.4%, respectively).  However, if premature discontinuations due to MAC or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> are excluded, approximately equal percentages of patients on each arm (54.8% on clarithromycin and 52.5% on placebo) discontinued study drug early for other reasons.  The study was designed to evaluate the following endpoints:</p>
<ol class="Arabic">
<li>MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, defined as at least one positive culture for <span class="Italics">M. avium</span> complex bacteria from blood or another normally sterile site.</li>
<li>Survival.</li>
<li>Clinically significant disseminated MAC disease, defined as MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> accompanied by signs or symptoms of serious MAC <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, or elevations in liver function tests.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73875"></a><a name="section-12.1.2"></a><p></p>
<h3>MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span></h3>
<p class="First">In patients randomized to clarithromycin, the risk of MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> was reduced by 69% compared to placebo.  The difference between groups was statistically significant (p &lt; 0.001).  On an intent-to-treat basis, the one-year cumulative incidence of MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> was 5.0% for patients randomized to clarithromycin and 19.4% for patients randomized to placebo.  While only 19 of the 341 patients randomized to clarithromycin developed MAC, 11 of these cases were resistant to clarithromycin.  The patients with resistant MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> had a median baseline CD<span class="Sub">4</span> count of 10 cells/mm<span class="Sup">3</span> (range 2 to 25 cells/mm<span class="Sup">3</span>).  Information regarding the clinical course and response to treatment of the patients with resistant MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> is limited.  The 8 patients who received clarithromycin and developed susceptible MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> had a median baseline CD<span class="Sub">4</span> count of 25 cells/mm<span class="Sup">3</span> (range 10 to 80 cells/mm<span class="Sup">3</span>).  Comparatively, 53 of the 341 placebo patients developed MAC; none of these isolates were resistant to clarithromycin.  The median baseline CD<span class="Sub">4</span> count was 15 cells/mm<span class="Sup">3</span> (range 2 to 130 cells/mm<span class="Sup">3</span>) for placebo patients that developed MAC.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN73928"></a><a name="section-12.1.3"></a><p></p>
<h3>Survival</h3>
<p class="First">A statistically significant survival benefit was observed.</p>
<p><span class="Bold">Survival  All Randomized Patients</span></p>
<div class="Figure"><img alt="Survival Graph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6&amp;name=biaxin-tab-survival-graph.jpg"></div>
<a name="table_22"></a><table width="100%">
<colgroup>
<col width="13%">
<col width="21%">
<col width="21%">
<col width="42%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Toprule" align="center"> </td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Mortality</span></td>
<td class="Toprule" align="center"><span class="Bold">Reduction in</span></td>
</tr>
<tr valign="bottom">
<td class="Botrule" align="center"> </td>
<td class="Botrule" align="center"><span class="Bold">Placebo</span></td>
<td class="Botrule" align="center"><span class="Bold">Clarithromycin</span></td>
<td class="Botrule" align="center"><span class="Bold">Mortality on Clarithromycin</span></td>
</tr>
<tr>
<td align="center">6 month</td>
<td align="center">9.4%</td>
<td align="center">6.5%</td>
<td align="center">31%</td>
</tr>
<tr>
<td align="center">12 month</td>
<td align="center">29.7%</td>
<td align="center">20.5%</td>
<td align="center">31%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">18 month</td>
<td class="Botrule" align="center">46.4%</td>
<td class="Botrule" align="center">37.5%</td>
<td class="Botrule" align="center">20%</td>
</tr>
</tbody>
</table>
<p>Since the analysis at 18 months includes patients no longer receiving prophylaxis the survival benefit of clarithromycin may be underestimated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN74122"></a><a name="section-12.1.4"></a><p></p>
<h3>Clinically Significant Disseminated MAC Disease</h3>
<p class="First">In association with the decreased incidence of <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, patients in the group randomized to clarithromycin showed reductions in the signs and symptoms of disseminated MAC disease, including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN74148"></a><a name="section-12.1.5"></a><p></p>
<h3>Safety</h3>
<p class="First">In AIDS patients treated with clarithromycin over long periods of time for prophylaxis against <span class="Italics">M. avium</span>, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> or intercurrent illness.  Median duration of treatment was 10.6 months for the clarithromycin group and 8.2 months for the placebo group.</p>
<a name="table_23"></a><table width="100%">
<caption><span>Treatment-related* Adverse Event Incidence Rates (%) in Immunocompromised Adult Patients Receiving Prophylaxis Against M. avium Complex</span></caption>
<colgroup>
<col width="37%">
<col width="31%">
<col width="30%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule">
<span class="Bold">Body System<span class="Sup">‡</span></span><br><span class="Bold"> Adverse Event</span>
</td>
<td class="Botrule Toprule" align="center"><span class="Bold">Clarithromycin<br>(n = 339)<br>%</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Placebo<br>(n = 339)<br>%</span></td>
</tr>
<tr>
<td><span class="Bold">Body as a Whole</span></td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center">5.0%</td>
<td align="center">3.5%</td>
</tr>
<tr>
<td>     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">2.7%</td>
<td align="center">0.9%</td>
</tr>
<tr>
<td><span class="Bold">Digestive</span></td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">7.7%</td>
<td align="center">4.1%</td>
</tr>
<tr>
<td>     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">3.8%</td>
<td align="center">2.7%</td>
</tr>
<tr>
<td>     <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="center">2.4%</td>
<td align="center">0.9%</td>
</tr>
<tr>
<td>     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">11.2%</td>
<td align="center">7.1%</td>
</tr>
<tr>
<td>     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">5.9%</td>
<td align="center">3.2%</td>
</tr>
<tr>
<td><span class="Bold">Skin &amp; Appendages </span></td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">3.2%</td>
<td align="center">3.5%</td>
</tr>
<tr>
<td><span class="Bold">Special Senses</span></td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>     <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span></td>
<td align="center">8.0%</td>
<td align="center">0.3%</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="3">*   Includes those events possibly or probably related to study drug and excludes concurrent conditions.<br>‡   &gt; 2% Adverse Event Incidence Rates for either treatment group.</td></tr>
</tbody>
</table>
<p>Among these events, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> was the only event that had significantly higher incidence in the clarithromycin-treated group compared to the placebo-treated group.</p>
<p>Discontinuation due to adverse events was required in 18% of patients receiving clarithromycin compared to 17% of patients receiving placebo in this trial.  Primary reasons for discontinuation in clarithromycin treated patients include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN74446"></a><a name="section-12.1.6"></a><p></p>
<h3>Changes in Laboratory Values of Potential Clinical Importance</h3>
<p class="First">In immunocompromised patients receiving prophylaxis against <span class="Italics">M. avium</span>, evaluations of laboratory values were made by analyzing those values outside the seriously abnormal value (i.e., the extreme high or low limit) for the specified test.</p>
<a name="table_24"></a><table width="100%">
<caption><span>Percentage of Patients<span class="Sup">(a)</span> Exceeding Extreme Laboratory Value in Patients Receiving Prophylaxis Against M. avium Complex</span></caption>
<colgroup>
<col width="18%">
<col width="23%">
<col width="30%">
<col width="27%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule" align="center" colspan="2"> </td>
<td class="Botrule Toprule" align="center" valign="top"><span class="Bold">Clarithromycin<br>500 mg b.i.d.</span></td>
<td class="Botrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td>Hemoglobin</td>
<td align="center">&lt; 8 g/dL</td>
<td align="center">4/118    3%</td>
<td align="center">5/103   5%</td>
</tr>
<tr>
<td>Platelet Count</td>
<td align="center">&lt; 50 x 10<span class="Sup">9</span>/L</td>
<td align="center">11/249    4%</td>
<td align="center">12/250   5%</td>
</tr>
<tr>
<td>WBC Count</td>
<td align="center">&lt; 1 x 10<span class="Sup">9</span>/L</td>
<td align="center">2/103     4%</td>
<td align="center">0/95   0%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span></td>
<td align="center">&gt; 5 x ULN<span class="Sup">(b)</span>
</td>
<td align="center">7/196    4%</td>
<td align="center">5/208   2%</td>
</tr>
<tr>
<td>SGPT</td>
<td align="center">&gt; 5 x ULN<span class="Sup">(b)</span>
</td>
<td align="center">6/217    3%</td>
<td align="center">4/232   2%</td>
</tr>
<tr>
<td>Alk. Phos.</td>
<td align="center">&gt; 5 x ULN<span class="Sup">(b)</span>
</td>
<td align="center">5/220    2%</td>
<td align="center">5/218   2%</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4">(a)   Includes only patients with baseline values within the normal range or borderline high (hematology variables) and within the normal range or borderline low (chemistry variables).<br>(b)   ULN = Upper Limit of  Normal</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN74671"></a><a name="section-12.1.7"></a><p></p>
<h3>Treatment</h3>
<p class="First">Three randomized studies (500, 577, and 521) compared different dosages of clarithromycin in patients with CDC-defined AIDS and CD<span class="Sub">4</span> counts &lt; 100 cells/µL.  These studies accrued patients from May 1991 to March 1992.  Study 500 was randomized, double-blind; Study 577 was open-label compassionate use.  Both studies used 500 and 1000 mg b.i.d. doses; Study 500 also had a 2000 mg b.i.d. group.  Study 521 was a pediatric study at 3.75, 7.5, and 15 mg/kg b.i.d.  Study 500 enrolled 154 adult patients, Study 577 enrolled 469 adult patients, and Study 521 enrolled 25 patients between the ages of 1 to 20.  The majority of patients had CD<span class="Sub">4</span> cell counts &lt; 50/µL at study entry.  The studies were designed to evaluate the following end points:</p>
<p>1. Change in MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> or blood cultures negative for <span class="Italics">M. avium</span>.</p>
<p>2. Change in clinical signs and symptoms of MAC <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> including one or more of the following:  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, and <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>.</p>
<p>The results for the 500 study are described below.  The 577 study results were similar to the results of the 500 study.  Results with the 7.5 mg/kg b.i.d. dose in the pediatric study were comparable to those for the 500 mg b.i.d. regimen in the adult studies.</p>
<p>Study 069 compared the safety and efficacy of clarithromycin in combination with ethambutol versus clarithromycin in combination with ethambutol and clofazimine for the treatment of disseminated MAC (dMAC) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.<span class="Sup">4</span>  This 24-week study enrolled 106 patients with AIDS and dMAC, with 55 patients randomized to receive clarithromycin and ethambutol, and 51 patients randomized to receive clarithromycin, ethambutol, and clofazimine.  Baseline characteristics between study arms were similar with the exception of median CFU counts being at least 1 log higher in the clarithromycin, ethambutol, and clofazimine arm.</p>
<p>Compared to prior experience with clarithromycin monotherapy, the two-drug regimen of clarithromycin and ethambutol was well tolerated and extended the time to microbiologic relapse, largely through suppressing the emergence of clarithromycin resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.  However, the addition of clofazimine to the regimen added no additional microbiologic or clinical benefit.  Tolerability of both multidrug regimens was comparable with the most common adverse events being gastrointestinal in nature.  Patients receiving the clofazimine-containing regimen had reduced survival rates; however, their baseline mycobacterial colony counts were higher.  The results of this trial support the addition of ethambutol to clarithromycin for the treatment of initial dMAC <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> but do not support adding clofazimine as a third agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN74725"></a><a name="section-12.1.8"></a><p></p>
<h3>MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span></h3>
<p class="First">Decreases in MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> or negative blood cultures were seen in the majority of patients in all dose groups.  Mean reductions in colony forming units (CFU) are shown below.  Included in the table are results from a separate study with a four drug regimen<span class="Sup">5</span> (ciprofloxacin, ethambutol, rifampicin, and clofazimine).  Since patient populations and study procedures may vary between these two studies, comparisons between the clarithromycin results and the combination therapy results should be interpreted cautiously.</p>
<a name="table_25"></a><table width="100%">
<caption><span>Mean Reductions in Log CFU from Baseline (After 4 Weeks of Therapy)</span></caption>
<colgroup>
<col width="24%">
<col width="25%">
<col width="25%">
<col width="24%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule" align="center"><span class="Bold">500 mg b.i.d.<br>(N = 35)</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">1000 mg b.i.d.<br>(N = 32)</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">2000 mg b.i.d.<br>(N = 26)</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Four Drug Regimen<br> (N = 24)</span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">1.5</td>
<td class="Botrule" align="center">2.3</td>
<td class="Botrule" align="center">2.3</td>
<td class="Botrule" align="center">1.4</td>
</tr>
</tbody>
</table>
<p>Although the 1000 mg and 2000 mg b.i.d. doses showed significantly better control of <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> during the first four weeks of therapy, no significant differences were seen beyond that point.  The percent of patients whose blood was sterilized as shown by one or more negative cultures at any time during acute therapy was 61% (30/49) for the 500 mg b.i.d. group and 59% (29/49) and 52% (25/48) for the 1000 and 2000 mg b.i.d. groups, respectively.  The percent of patients who had 2 or more negative cultures during acute therapy that were sustained through study Day 84 was 25% (12/49) in both the 500 and 1000 mg b.i.d. groups and 8% (4/48) for the 2000 mg b.i.d. group.  By Day 84, 23% (11/49), 37% (18/49), and 56% (27/48) of patients had died or discontinued from the study, and 14% (7/49), 12% (6/49), and 13% (6/48) of patients had relapsed in the 500, 1000, and 2000 mg b.i.d. dose groups, respectively.  All of the isolates had an MIC &lt; 8 µg/mL at pre-treatment.  Relapse was almost always accompanied by an increase in MIC.  The median time to first negative culture was 54, 41, and 29 days for the 500, 1000, and 2000 mg b.i.d. groups, respectively.  The time to first decrease of at least 1 log in CFU count was significantly shorter with the 1000 and 2000 mg b.i.d. doses (median equal to 16 and 15 days, respectively) in comparison to the 500 mg b.i.d. group (median equal to 29 days).  The median time to first positive culture or study discontinuation following the first negative culture was 43, 59 and 43 days for the 500, 1000, and 2000 mg b.i.d. groups, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN74847"></a><a name="section-12.1.9"></a><p></p>
<h3>Clinically Significant Disseminated MAC Disease</h3>
<p class="First">Among patients experiencing <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span> prior to therapy, 84% showed resolution or improvement at some point during the 12 weeks of clarithromycin at 500 to 2000 mg b.i.d. doses.  Similarly, 77% of patients reported resolution or improvement in <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> at some point.  Response rates for clinical signs of MAC are given below:</p>
<a name="table_26"></a><table width="100%">
<colgroup>
<col width="14%">
<col width="15%">
<col width="15%">
<col width="17%">
<col width="16%">
<col width="15%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Toprule" align="center" colspan="3"><span class="Bold">Resolution of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></td>
<td class="Toprule" align="center" colspan="3"><span class="Bold">Resolution of <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night Sweats</span></span></td>
</tr>
<tr valign="top">
<td class="Botrule" align="center">b.i.d. <br>dose<br>(mg)</td>
<td class="Botrule" align="center">% ever<br>afebrile</td>
<td class="Botrule" align="center">%<br>afebrile<br>≥ 6 weeks</td>
<td class="Botrule" align="center">b.i.d.<br>dose<br>(mg)</td>
<td class="Botrule" align="center">% ever<br>resolving</td>
<td class="Botrule" align="center">%<br>resolving<br>≥ 6 weeks</td>
</tr>
<tr>
<td align="center">500</td>
<td align="center">67%</td>
<td align="center">23%</td>
<td align="center">500</td>
<td align="center">85%</td>
<td align="center">42%</td>
</tr>
<tr>
<td align="center">1000</td>
<td align="center">67%</td>
<td align="center">12%</td>
<td align="center">1000</td>
<td align="center">70%</td>
<td align="center">33%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">2000</td>
<td class="Botrule" align="center">62%</td>
<td class="Botrule" align="center">22%</td>
<td class="Botrule" align="center">2000</td>
<td class="Botrule" align="center">72%</td>
<td class="Botrule" align="center">36%</td>
</tr>
</tbody>
</table>
<a name="table_27"></a><table width="100%">
<colgroup>
<col width="14%">
<col width="16%">
<col width="16%">
<col width="17%">
<col width="17%">
<col width="16%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Toprule" align="center" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> &gt; 3%</span></td>
<td class="Toprule" align="center" colspan="3"><span class="Bold">Hemoglobin Increase &gt; 1 gm</span></td>
</tr>
<tr valign="top">
<td class="Botrule" align="center">b.i.d.<br>dose<br>(mg)</td>
<td class="Botrule" align="center">% ever<br>gaining</td>
<td class="Botrule" align="center">%<br>gaining<br>≥ 6 weeks</td>
<td class="Botrule" align="center">b.i.d.<br>dose<br>(mg)</td>
<td class="Botrule" align="center">% ever<br>increasing</td>
<td class="Botrule" align="center">%<br>increasing<br>≥ 6 weeks</td>
</tr>
<tr>
<td align="center">500</td>
<td align="center">33%</td>
<td align="center">14%</td>
<td align="center">500</td>
<td align="center">58%</td>
<td align="center">26%</td>
</tr>
<tr>
<td align="center">1000</td>
<td align="center">26%</td>
<td align="center">17%</td>
<td align="center">1000</td>
<td align="center">37%</td>
<td align="center">6%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">2000</td>
<td class="Botrule" align="center">26%</td>
<td class="Botrule" align="center">12%</td>
<td class="Botrule" align="center">2000</td>
<td class="Botrule" align="center">62%</td>
<td class="Botrule" align="center">18%</td>
</tr>
</tbody>
</table>
<p>The median duration of response, defined as improvement or resolution of clinical signs and symptoms, was 2 to 6 weeks.</p>
<p>Since the study was not designed to determine the benefit of monotherapy beyond 12 weeks, the duration of response may be underestimated for the 25 to 33% of patients who continued to show clinical response after 12 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN75243"></a><a name="section-12.1.10"></a><p></p>
<h3>Survival</h3>
<p class="First">Median survival time from study entry (Study 500) was 249 days at the 500 mg b.i.d. dose compared to 215 days with the 1000 mg b.i.d. dose.  However, during the first 12 weeks of therapy, there were 2 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in 53 patients in the 500 mg b.i.d. group versus 13 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in 51 patients in the 1000 mg b.i.d. group.  The reason for this apparent mortality difference is not known.  Survival in the two groups was similar beyond 12 weeks.  The median survival times for these dosages were similar to recent historical controls with MAC when treated with combination therapies.<span class="Sup">5</span></p>
<p>Median survival time from study entry in Study 577 was 199 days for the 500 mg b.i.d. dose and 179 days for the 1000 mg b.i.d. dose.  During the first four weeks of therapy, while patients were maintained on their originally assigned dose, there were 11 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in 255 patients taking 500 mg b.i.d. and 18 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in 214 patients taking 1000 mg b.i.d.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN75275"></a><a name="section-12.1.11"></a><p></p>
<h3>Safety</h3>
<p class="First">The adverse event profiles showed that both the 500 and 1000 mg b.i.d. doses were well tolerated.  The 2000 mg b.i.d. dose was poorly tolerated and resulted in a higher proportion of premature discontinuations.</p>
<p>In AIDS patients and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span>, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying signs of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> or intercurrent illness.</p>
<p>The following analyses summarize experience during the first 12 weeks of therapy with clarithromycin.  Data are reported separately for Study 500 (randomized, double-blind) and Study 577 (open-label, compassionate use) and also combined.  Adverse events were reported less frequently in Study 577, which may be due in part to differences in monitoring between the two studies.  In adult patients receiving clarithromycin 500 mg b.i.d., the most frequently reported adverse events, considered possibly or probably related to study drug, with an incidence of 5% or greater, are listed below.  Most of these events were mild to moderate in severity, although 5% (Study 500:  8%; Study 577:  4%) of patients receiving 500 mg b.i.d. and 5% (Study 500:  4%; Study 577:  6%) of patients receiving 1000 mg b.i.d. reported severe adverse events.  Excluding those patients who discontinued therapy or died due to complications of their underlying non-mycobacterial disease, approximately 8% (Study 500:  15%; Study 577:  7%) of the patients who received 500 mg b.i.d. and 12% (Study 500:  14%; Study 577:  12%) of the patients who received 1000 mg b.i.d. discontinued therapy due to drug-related events during the first 12 weeks of therapy.  Overall, the 500 and 1000 mg b.i.d. doses had similar adverse event profiles.</p>
<a name="table_28"></a><table width="100%">
<caption><span>Treatment-related* Adverse Event Incidence Rates (%) in Immunocompromised Adult Patients During the First 12 Weeks of Therapy with 500 mg b.i.d. Clarithromycin Dose</span></caption>
<colgroup>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="24%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule"><span class="Bold">Adverse Event</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Study 500<br>(n = 53)</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Study 577<br>(n = 255)</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Combined<br>(n = 308)</span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center">7.5</td>
<td align="center">2.4</td>
<td align="center">3.2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">9.4</td>
<td align="center">1.6</td>
<td align="center">2.9</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="center">7.5</td>
<td align="center">0.0</td>
<td align="center">1.3</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">7.5</td>
<td align="center">0.4</td>
<td align="center">1.6</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">28.3</td>
<td align="center">9.0</td>
<td align="center">12.3</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">9.4</td>
<td align="center">2.0</td>
<td align="center">3.2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span></td>
<td align="center">18.9</td>
<td align="center">0.4</td>
<td align="center">3.6</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">24.5</td>
<td align="center">3.9</td>
<td align="center">7.5</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4">*   Includes those events possibly or probably related to study drug and excludes concurrent conditions.</td></tr>
</tbody>
</table>
<p>A limited number of pediatric AIDS patients have been treated with clarithromycin suspension for <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span>.  The most frequently reported adverse events, excluding those due to the patient's concurrent condition, were consistent with those observed in adult patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN75535"></a><a name="section-12.1.12"></a><p></p>
<h3>Changes in Laboratory Values</h3>
<p class="First">In immunocompromised patients treated with clarithromycin for <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span>, evaluations of laboratory values were made by analyzing those values outside the seriously abnormal level (i.e., the extreme high or low limit) for the specified test.</p>
<a name="table_29"></a><table width="100%">
<caption><span>Percentage of Patients<span class="Sup">(a)</span> Exceeding Extreme Laboratory Value Limits During First 12 Weeks of Treatment 500 mg b.i.d. Dose<span class="Sup">(b)</span></span></caption>
<colgroup>
<col width="19%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="19%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule" align="center"> </td>
<td class="Botrule Toprule" align="center"> </td>
<td class="Botrule Toprule" align="center"><span class="Bold">Study 500</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Study 577</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Combined</span></td>
</tr>
<tr>
<td>BUN</td>
<td align="center">&gt; 50 mg/dL</td>
<td align="center">0%</td>
<td align="center">&lt; 1%</td>
<td align="center">&lt; 1%</td>
</tr>
<tr>
<td>Platelet Count</td>
<td align="center">&lt; 50 x 10<span class="Sup">9</span>/L</td>
<td align="center">0%</td>
<td align="center">&lt; 1%</td>
<td align="center">&lt; 1%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span></td>
<td align="center">&gt; 5 x ULN<span class="Sup">(c)</span>
</td>
<td align="center">0%</td>
<td align="center">3%</td>
<td align="center">2%</td>
</tr>
<tr>
<td>SGPT</td>
<td align="center">&gt; 5 x ULN<span class="Sup">(c)</span>
</td>
<td align="center">0%</td>
<td align="center">2%</td>
<td align="center">1%</td>
</tr>
<tr>
<td>WBC</td>
<td align="center">&lt; 1 x 10<span class="Sup">9</span>/L</td>
<td align="center">0%</td>
<td align="center">1%</td>
<td align="center">1%</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="5">(a)   Includes only patients with baseline values within the normal range or borderline high (hematology variables) and within the normal range or borderline low (chemistry variables)<br>(b)   Includes all values within the first 12 weeks for patients who start on 500 mg b.i.d.<br>(c)   ULN = Upper Limit of  Normal</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN75774"></a><a name="section-12.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></h2>
<p class="First">In a controlled clinical study of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> performed in the  United States, where significant rates of beta-lactamase producing organisms were found, clarithromycin was compared to an oral cephalosporin.  In this study, very strict evaluability criteria were used to determine clinical response.  For the 223 patients who were evaluated for clinical efficacy, the clinical success rate (i.e., cure plus improvement) at the post-therapy visit was 88% for clarithromycin and 91% for the cephalosporin.</p>
<p>In a smaller number of patients, microbiologic determinations were made at the pre-treatment visit.  The following presumptive bacterial eradication/clinical cure outcomes (i.e., clinical success) were obtained:</p>
<a name="table_30"></a><table width="100%">
<caption><span>U.S. Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> Study Clarithromycin vs. Oral Cephalosporin EFFICACY RESULTS</span></caption>
<colgroup>
<col width="24%">
<col width="66%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"><span class="Bold">PATHOGEN</span></td>
<td class="Botrule Toprule"><span class="Bold">OUTCOME</span></td>
</tr>
<tr>
<td><span class="Italics">S. pneumoniae</span></td>
<td>clarithromycin success rate, 13/15 (87%), control 4/5</td>
</tr>
<tr>
<td><span class="Italics">H. influenzae*</span></td>
<td>clarithromycin success rate, 10/14 (71%), control 3/4</td>
</tr>
<tr>
<td><span class="Italics">M. catarrhalis</span></td>
<td>clarithromycin success rate, 4/5,control 1/1</td>
</tr>
<tr>
<td><span class="Italics">S. pyogenes</span></td>
<td>clarithromycin success rate, 3/3,control 0/1</td>
</tr>
<tr>
<td>Overall</td>
<td>clarithromycin success rate, 30/37 (81%), control 8/11 (73%)</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="2">*   None of the <span class="Italics">H. influenzae</span> isolated pre-treatment was resistant to clarithromycin; 6% were resistant to the control agent.</td></tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="GN75917"></a><a name="section-12.2.1"></a><p></p>
<h3>Safety</h3>
<p class="First">The incidence of adverse events in all patients treated, primarily <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, did not differ clinically or statistically for the two agents.</p>
<p>In two other controlled clinical trials of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> performed in the  United States, where significant rates of beta-lactamase producing organisms were found, clarithromycin was compared to an oral antimicrobial agent that contained a specific beta-lactamase inhibitor.  In these studies, very strict evaluability criteria were used to determine the clinical responses.  In the 233 patients who were evaluated for clinical efficacy, the combined clinical success rate (i.e., cure and improvement) at the post-therapy visit was 91% for both clarithromycin and the control.</p>
<p>For the patients who had microbiologic determinations at the pre-treatment visit, the following presumptive bacterial eradication/clinical cure outcomes (i.e., clinical success) were obtained:</p>
<a name="table_31"></a><table width="100%">
<caption><span>Two U.S. Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> Studies Clarithromycin vs. Antimicrobial/Beta-lactamase Inhibitor EFFICACY RESULTS</span></caption>
<colgroup>
<col width="27%">
<col width="63%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"><span class="Bold">PATHOGEN</span></td>
<td class="Botrule Toprule"><span class="Bold">OUTCOME</span></td>
</tr>
<tr>
<td><span class="Italics">S. pneumoniae</span></td>
<td>clarithromycin success rate, 43/51 (84%), control 55/56 (98%)</td>
</tr>
<tr>
<td><span class="Italics">H. influenzae*</span></td>
<td>clarithromycin success rate, 36/45 (80%), control 31/33 (94%)</td>
</tr>
<tr>
<td><span class="Italics">M. catarrhalis</span></td>
<td>clarithromycin success rate, 9/10 (90%), control 6/6</td>
</tr>
<tr>
<td><span class="Italics">S. pyogenes</span></td>
<td>clarithromycin success rate, 3/3, control 5/5</td>
</tr>
<tr>
<td>Overall</td>
<td>clarithromycin success rate, 91/109 (83%), control 97/100 (97%)</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="2">*   Of the <span class="Italics">H. influenzae  </span> isolated pre-treatment, 3% were resistant to clarithromycin and 10% were resistant to the control agent.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76064"></a><a name="section-12.2.2"></a><p></p>
<h3>Safety</h3>
<p class="First">The incidence of adverse events in all patients treated, primarily <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (15% vs. 38%) and <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> (3% vs. 11%) in young children, was clinically and statistically lower in the clarithromycin arm versus the control arm.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76092"></a><a name="section-12.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Associated with <span class="Italics">H. pylori  </span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76119"></a><a name="section-12.3.1"></a><p></p>
<h3>Clarithromycin + Lansoprazole and Amoxicillin</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76142"></a><a name="section-12.3.1.1"></a><p></p>
<h4>
<span class="Italics">H. pylori</span> Eradication for Reducing the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence</h4>
<p class="First">Two  U.S. randomized, double-blind clinical studies in patients with <span class="Italics">H. pylori</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (defined as an active <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or history of an active <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> within one year) evaluated the efficacy of clarithromycin in combination with lansoprazole and amoxicillin capsules as triple 14-day therapy for eradication of <span class="Italics">H. pylori</span>.  Based on the results of these studies, the safety and efficacy of the following eradication regimen were established:</p>
<p>Triple therapy:  BIAXIN (clarithromycin) 500 mg b.i.d. + lansoprazole 30 mg b.i.d. + amoxicillin 1 gm b.i.d.</p>
<p>Treatment was for 14 days.  <span class="Italics">H. pylori</span> eradication was defined as two negative tests (culture and histology) at 4 to 6 weeks following the end of treatment.</p>
<p>The combination of BIAXIN plus lansoprazole and amoxicillin as triple therapy was effective in eradicating <span class="Italics">H. pylori</span>.  Eradication of <span class="Italics">H. pylori</span> has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence.</p>
<p>A randomized, double-blind clinical study performed in the  U.S. in patients with <span class="Italics">H. pylori  </span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (defined as an active <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or history of an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> within one year) compared the efficacy of clarithromycin in combination with lansoprazole and amoxicillin as triple therapy for 10 and 14 days.  This study established that the 10-day triple therapy was equivalent to the 14-day triple therapy in eradicating <span class="Italics">H. pylori</span>.</p>
<a name="table_32"></a><table width="100%">
<caption><span>H. pylori Eradication Rates-Triple Therapy (BIAXIN/lansoprazole/amoxicillin) Percent of Patients Cured [95% Confidence Interval] (number of patients)</span></caption>
<colgroup>
<col width="16%">
<col width="16%">
<col width="33%">
<col width="33%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule" align="center"><span class="Bold">Study</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Duration</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Triple Therapy<br>Evaluable Analysis*</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Triple Therapy<br>Intent-to-Treat Analysis<span class="Sup">#</span></span></td>
</tr>
<tr>
<td>M93-131</td>
<td align="center">14 days</td>
<td align="center">92<span class="Sup">†</span> [80.0-97.7]<br>(n = 48)</td>
<td align="center">86<span class="Sup">†</span> [73.3-93.5]<br>(n = 55)</td>
</tr>
<tr>
<td>M95-392</td>
<td align="center">14 days</td>
<td align="center">86<span class="Sup">‡</span> [75.7-93.6]<br>(n = 66)</td>
<td align="center">83<span class="Sup">‡</span> [72.0-90.8]<br>(n = 70)</td>
</tr>
<tr>
<td>M95-399¶ 															</td>
<td align="center">14 days</td>
<td align="center">85 [77.0-91.0]<br>(N = 113)</td>
<td align="center">82 [73.9-88.1]<br>(N = 126)</td>
</tr>
<tr>
<td> </td>
<td align="center">10 days</td>
<td align="center">84 [76.0-89.8]<br>(N = 123)</td>
<td align="center">81 [73.9-87.6]<br>(N = 135)</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4">*   Based on evaluable patients with confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within one year) and <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline defined as at least two of three positive endoscopic tests from CLOtest (Delta West LTD., Bentley, Australia), histology, and/or culture.  Patients were included in the analysis if they completed the study.  Additionally, if patients were dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as evaluable failures of therapy.<br>#   Patients were included in the analysis if they had documented <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline as defined above and had a confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within one year).  All dropouts were included as failures of therapy.<br>†   (p &lt; 0.05) versus BIAXIN/lansoprazole and lansoprazole/amoxicillin dual therapy.<br>‡   (p &lt; 0.05) versus BIAXIN/amoxicillin dual therapy.<br><p class="First"></p>¶   The 95% confidence interval for the difference in eradication rates, 10-day minus 14-day, is (-10.5, 8.1) in the evaluable analysis and (-9.7, 9.1) in the intent-to-treat analysis.</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76414"></a><a name="section-12.3.2"></a><p></p>
<h3>Clarithromycin + Omeprazole and Amoxicillin Therapy</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76437"></a><a name="section-12.3.2.1"></a><p></p>
<h4>
<span class="Italics">H. pylori </span>Eradication for Reducing the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence</h4>
<p class="First">Three  U.S., randomized, double-blind clinical studies in patients with <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (n = 558) compared clarithromycin plus omeprazole and amoxicillin to clarithromycin plus amoxicillin.  Two studies (Studies 126 and 127) were conducted in patients with an active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, and the third study (Study 446) was conducted in patients with a <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> in the past 5 years, but without an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> present at the time of enrollment.  The dosage regimen in the studies was clarithromycin 500 mg b.i.d. plus omeprazole 20 mg b.i.d. plus amoxicillin 1 gram b.i.d. for 10 days.  In Studies 126 and 127, patients who took the omeprazole regimen also received an additional 18 days of omeprazole 20 mg q.d.  Endpoints studied were eradication of <span class="Italics">H. pylori</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> healing (studies 126 and 127 only).  <span class="Italics">H. pylori</span> status was determined by CLOtest<span class="Sup">®</span>, histology, and culture in all three studies.  For a given patient, <span class="Italics">H. pylori  </span> was considered eradicated if at least two of these tests were negative, and none was positive.  The combination of clarithromycin plus omeprazole and amoxicillin was effective in eradicating <span class="Italics">H. pylori</span>.</p>
<a name="table_33"></a><table width="100%">
<caption><span>Per-Protocol and Intent-to-Treat H. pylori Eradication Rates % of Patients Cured [95% Confidence Interval]</span></caption>
<colgroup>
<col width="17%">
<col width="20%">
<col width="21%">
<col width="19%">
<col width="20%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule" align="center"> </td>
<td class="Botrule Toprule" align="center" colspan="2"><span class="Bold">Clarithromycin + omeprazole + amoxicillin</span></td>
<td class="Botrule Toprule" align="center" colspan="2"><span class="Bold">Clarithromycin + amoxicillin</span></td>
</tr>
<tr valign="bottom">
<td align="center"> </td>
<td align="center"><span class="Bold">Per-Protocol  <span class="Sup">†</span></span></td>
<td align="center"><span class="Bold">Intent-to-Treat  <span class="Sup">‡</span></span></td>
<td align="center"><span class="Bold">Per-Protocol  <span class="Sup">†</span></span></td>
<td align="center"><span class="Bold">Intent-to-Treat  <span class="Sup">‡</span></span></td>
</tr>
<tr valign="top">
<td>Study 126</td>
<td align="center">*77 [64, 86]<br>(n = 64)</td>
<td align="center">69 [57, 79]<br>(n = 80)</td>
<td align="center">43 [31, 56]<br>(n = 67)</td>
<td align="center">37 [27, 48]<br>(n = 84)</td>
</tr>
<tr valign="top">
<td>Study 127</td>
<td align="center">*78 [67, 88]<br>(n = 65)</td>
<td align="center">73 [61, 82]<br>(n = 77)</td>
<td align="center">41 [29, 54]<br>(n = 68)</td>
<td align="center">36 [26, 47]<br>(n = 84)</td>
</tr>
<tr valign="top">
<td>Study M96-446</td>
<td align="center">*90 [80, 96]<br>(n = 69)</td>
<td align="center">83 [74, 91]<br>(n = 84)</td>
<td align="center">33 [24, 44]<br>(n = 93)</td>
<td align="center">32 [23, 42]<br>(n = 99)</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="5">†   Patients were included in the analysis if they had confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> studies 126 and 127; history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> within 5 years, study M96-446) and <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline defined as at least two of three positive endoscopic tests from CLOtest<span class="Sup">®</span>, histology, and/or culture.  Patients were included in the analysis if they completed the study.  Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy.  The impact of eradication on <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> recurrence has not been assessed in patients with a past history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>.<br>‡   Patients were included in the analysis if they had documented <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline and had confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease.  All dropouts were included as failures of therapy.<br>*   p &lt; 0.05 versus clarithromycin plus amoxicillin.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76711"></a><a name="section-12.3.2.2"></a><p></p>
<h4>Safety</h4>
<p class="First">In clinical trials using combination therapy with clarithromycin plus omeprazole and amoxicillin, no adverse reactions peculiar to the combination of these drugs have been observed.  Adverse reactions that have occurred have been limited to those that have been previously reported with clarithromycin, omeprazole, or amoxicillin.</p>
<p>The most frequent adverse experiences observed in clinical trials using combination therapy with clarithromycin plus omeprazole and amoxicillin (n = 274) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (14%), <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> (10%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7%).</p>
<p>For information about adverse reactions with omeprazole or amoxicillin, refer to the <span class="Bold">ADVERSE REACTIONS</span> section of their package inserts.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76749"></a><a name="section-12.3.3"></a><p></p>
<h3>Clarithromycin + Omeprazole Therapy</h3>
<p class="First">Four randomized, double-blind, multi-center studies (067, 100, 812b, and 058) evaluated clarithromycin 500 mg t.i.d. plus omeprazole 40 mg q.d. for 14 days, followed by omeprazole 20 mg q.d. (067, 100, and 058) or by omeprazole 40 mg q.d. (812b) for an additional 14 days in patients with active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> associated with <span class="Italics">H. pylori  </span>.  Studies 067 and 100 were conducted in the  U.S. and  Canada and enrolled 242 and 256 patients, respectively.  <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> were confirmed in 219 patients in Study 067 and 228 patients in Study 100.  These studies compared the combination regimen to omeprazole and clarithromycin monotherapies.  Studies 812b and 058 were conducted in  Europe and enrolled 154 and 215 patients, respectively.  <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> were confirmed in 148 patients in Study 812b and 208 patients in Study 058.  These studies compared the combination regimen to omeprazole monotherapy.  The results for the efficacy analyses for these studies are described below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76785"></a><a name="section-12.3.3.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Healing</h4>
<p class="First">The combination of clarithromycin and omeprazole was as effective as omeprazole alone for healing <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>.</p>
<a name="table_34"></a><table width="100%">
<caption><span>End-of-Treatment <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Healing Rates Percent of Patients Healed (n/N)</span></caption>
<colgroup>
<col width="31%">
<col width="23%">
<col width="23%">
<col width="21%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule"><span class="Bold">Study</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Clarithromycin + Omeprazole</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Omeprazole</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Clarithromycin</span></td>
</tr>
<tr><td colspan="4"><span class="Bold">U.S. Studies</span></td></tr>
<tr>
<td>     Study 100</td>
<td align="center">94% (58/62)<span class="Sup">†</span>
</td>
<td align="center">88% (60/68)</td>
<td align="center">71% (49/69)</td>
</tr>
<tr>
<td>     Study 067 						 					 		</td>
<td align="center">88% (56/64)<span class="Sup">†</span>
</td>
<td align="center">85% (55/65)</td>
<td align="center">64% (44/69)</td>
</tr>
<tr><td colspan="4"><span class="Bold">Non-U.S. Studies</span></td></tr>
<tr>
<td>     Study 058 						 					 		</td>
<td align="center">99% (84/85)</td>
<td align="center">95% (82/86)</td>
<td align="center">N/A</td>
</tr>
<tr>
<td>     Study 812b<span class="Sup">1</span>
</td>
<td align="center">100% (64/64)</td>
<td align="center">99% (71/72)</td>
<td align="center">N/A</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4">†   p &lt; 0.05 for clarithromycin + omeprazole versus clarithromycin monotherapy.<br>1   In Study 812b patients received omeprazole 40 mg daily for days 15 to 28.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN76993"></a><a name="section-12.3.3.2"></a><p></p>
<h4>Eradication of <span class="Italics">H. pylori </span>Associated with <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></h4>
<p class="First">The combination of clarithromycin and omeprazole was effective in eradicating <span class="Italics">H. pylori</span>.</p>
<a name="table_35"></a><table width="100%">
<caption><span>H. pylori Eradication Rates (Per-Protocol Analysis) at 4 to 6 weeks Percent of Patients Cured (n/N)</span></caption>
<colgroup>
<col width="24%">
<col width="25%">
<col width="25%">
<col width="24%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Botrule Toprule"><span class="Bold">Study</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Clarithromycin + Omeprazole</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Omeprazole</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Clarithromycin</span></td>
</tr>
<tr><td colspan="4"><span class="Bold"> U.S. Studies</span></td></tr>
<tr>
<td>     Study 100</td>
<td align="center">64% (39/61)<span class="Sup">†‡</span>
</td>
<td align="center">0% (0/59)</td>
<td align="center">39% (17/44)</td>
</tr>
<tr>
<td>     Study 067</td>
<td align="center">74% (39/53)<span class="Sup">†‡</span>
</td>
<td align="center">0% (0/54)</td>
<td align="center">31% (13/42)</td>
</tr>
<tr><td colspan="4"><span class="Bold">Non-U.S. Studies  </span></td></tr>
<tr>
<td>     Study 058</td>
<td align="center">74% (64/86)<span class="Sup">‡</span>
</td>
<td align="center">1% (1/90)</td>
<td align="center">N/A</td>
</tr>
<tr>
<td>     Study 812b</td>
<td align="center">83% (50/60)<span class="Sup">‡</span>
</td>
<td align="center">1% (1/74)</td>
<td align="center">N/A</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4">†   Statistically significantly higher than clarithromycin monotherapy (p &lt; 0.05).<br>‡   Statistically significantly higher than omeprazole monotherapy (p &lt; 0.05).</td></tr>
</tbody>
</table>
<p><span class="Italics">H. pylori</span> eradication was defined as no positive test (culture or histology) at 4 weeks following the end of treatment, and two negative tests were required to be considered eradicated.  In the per-protocol analysis, the following patients were excluded:  dropouts, patients with major protocol violations, patients with missing <span class="Italics">H. pylori</span> tests post-treatment, and patients that were not assessed for <span class="Italics">H. pylori</span> eradication at 4 weeks after the end of treatment because they were found to have an unhealed <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> at the end of treatment.</p>
<p><span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> recurrence at 6-months following the end of treatment was assessed for patients in whom <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> were healed post-treatment.</p>
<a name="table_36"></a><table width="100%">
<caption><span><span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Recurrence at 6 months by H. pylori Status at 4-6 Weeks</span></caption>
<colgroup>
<col width="20%">
<col width="20%">
<col width="29%">
<col width="28%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule" align="center" colspan="2"> </td>
<td class="Botrule Toprule" align="center">
<span class="Italics"><span class="Bold">H. pylori</span></span><span class="Bold"> Negative</span>
</td>
<td class="Botrule Toprule" align="center">
<span class="Italics"><span class="Bold">H. pylori</span></span><span class="Bold"> Positive</span>
</td>
</tr>
<tr><td colspan="4" valign="bottom"><span class="Bold"> U.S. Studies </span></td></tr>
<tr valign="bottom">
<td><span class="Bold"> Study 100</span></td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td colspan="2">     Clarithromycin + Omeprazole</td>
<td align="center">6% (2/34)</td>
<td align="center">56% (9/16)</td>
</tr>
<tr>
<td colspan="2">     Omeprazole</td>
<td align="center">-   (0/0)</td>
<td align="center">71% (35/49)</td>
</tr>
<tr>
<td colspan="2">     Clarithromycin</td>
<td align="center">12% (2/17)</td>
<td align="center">32% (7/22)</td>
</tr>
<tr>
<td colspan="2"> <span class="Bold">Study 067</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td colspan="2">     Clarithromycin + Omeprazole</td>
<td align="center">38% (11/29)</td>
<td align="center">50% (6/12)</td>
</tr>
<tr>
<td colspan="2">     Omeprazole</td>
<td align="center">-    (0/0)</td>
<td align="center">67% (31/46)</td>
</tr>
<tr>
<td colspan="2">     Clarithromycin</td>
<td align="center">18% (2/11)</td>
<td align="center">52% (14/27)</td>
</tr>
<tr><td colspan="4"><span class="Bold">Non-U.S. Studies</span></td></tr>
<tr>
<td><span class="Bold"> Study 058</span></td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td colspan="2">     Clarithromycin + Omeprazole</td>
<td align="center">6% (3/53)</td>
<td align="center">24% (4/17)</td>
</tr>
<tr>
<td colspan="2">     Omeprazole</td>
<td align="center">0% (0/3)</td>
<td align="center">55% (39/71)</td>
</tr>
<tr>
<td colspan="2"><span class="Bold">Study 812b*</span></td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td colspan="2">     Clarithromycin + Omeprazole</td>
<td align="center">5% (2/42)</td>
<td align="center">0% (0/7)</td>
</tr>
<tr>
<td colspan="2">     Omeprazole</td>
<td align="center">0% (0/1)</td>
<td align="center">54% (32/59)</td>
</tr>
<tr>
<td colspan="2"><span class="Bold">*12-month recurrence rates:</span></td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td colspan="2">     Clarithromycin + Omeprazole</td>
<td align="center">3% (1/40)</td>
<td align="center">0% (0/6)</td>
</tr>
<tr class="Last">
<td class="Botrule" colspan="2">     Omeprazole</td>
<td class="Botrule" align="center">0% (0/1)</td>
<td class="Botrule" align="center">67% (29/43)</td>
</tr>
</tbody>
</table>
<p>Thus, in patients with <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> associated with <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, eradication of <span class="Italics">H. pylori</span> reduced <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> recurrence.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN77589"></a><a name="section-12.3.3.3"></a><p></p>
<h4>Safety</h4>
<p class="First">The adverse event profiles for the four studies showed that the combination of clarithromycin 500 mg t.i.d. and omeprazole 40 mg q.d. for 14 days, followed by omeprazole 20 mg q.d. (067, 100, and 058) or 40 mg q.d. (812b) for an additional 14 days was well tolerated.  Of the 346 patients who received the combination, 12 (3.5%) patients discontinued study drug due to adverse events. </p>
<a name="table_37"></a><table width="100%">
<caption><span>Adverse Events with an Incidence of 3% or Greater</span></caption>
<colgroup>
<col width="22%">
<col width="22%">
<col width="22%">
<col width="22%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule"><span class="Bold">Adverse Event</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Clarithromycin + Omeprazole<br>(N = 346)<br>% of Patients</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Omeprazole<br>(N = 355)<br>% of Patients</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">Clarithromycin<br>(N = 166)<br>% of Patients*</span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span></td>
<td align="center">15%</td>
<td align="center">1%</td>
<td align="center">16%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">5%</td>
<td align="center">1%</td>
<td align="center">3%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">5%</td>
<td align="center">6%</td>
<td align="center">9%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">4%</td>
<td align="center">3%</td>
<td align="center">7%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">4%</td>
<td align="center">&lt; 1%</td>
<td align="center">1%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center">3%</td>
<td align="center">2%</td>
<td align="center">1%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="center">3%</td>
<td align="center">4%</td>
<td align="center">2%</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4">*   Studies 067 and 100, only.</td></tr>
</tbody>
</table>
<p>Most of these events were mild to moderate in severity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN77834"></a><a name="section-12.3.3.4"></a><p></p>
<h4>Changes in Laboratory Values</h4>
<p class="First">Changes in laboratory values with possible clinical significance in patients taking clarithromycin and omeprazole were as follows:</p>
<p>Hepatic - elevated direct bilirubin &lt; 1%; GGT &lt; 1%; <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST) &lt; 1%; SGPT (ALT) &lt; 1%.</p>
<p>Renal - elevated serum creatinine &lt; 1%.</p>
<p>For information on omeprazole, refer to the <span class="Bold">ADVERSE REACTIONS</span> section of the PRILOSEC package insert.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN77875"></a><a name="section-12.3.4"></a><p></p>
<h3>Clarithromycin + Ranitidine Bismuth Citrate Therapy</h3>
<p class="First">In a U.S. double-blind, randomized, multicenter, dose-comparison trial, ranitidine bismuth citrate 400 mg b.i.d. for 4 weeks plus clarithromycin 500 mg b.i.d. for the first 2 weeks was found to have an equivalent <span class="Italics">H. pylori</span> eradication rate (based on culture and histology) when compared to ranitidine bismuth citrate 400 mg b.i.d. for 4 weeks plus clarithromycin 500 mg t.i.d. for the first 2 weeks.  The intent-to-treat <span class="Italics">H. pylori  </span> eradication rates are shown below:</p>
<a name="table_38"></a><table width="100%">
<caption><span>H. pylori Eradication Rates in Study H2BA-3001</span></caption>
<colgroup>
<col width="15%">
<col width="27%">
<col width="29%">
<col width="27%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Toprule"><span class="Bold">Analysis</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">RBC 400 mg + Clarithromycin<br>500 mg b.i.d.</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">RBC 400 mg + Clarithromycin<br>500 mg t.i.d.</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">95% CI Rate Difference</span></td>
</tr>
<tr valign="top">
<td>ITT</td>
<td align="center">65% (122/188)<br>[58%, 72%]</td>
<td align="center">63% (122/195)<br>[55%, 69%]</td>
<td align="center">(-8%, 12%)</td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule">Per-Protocol</td>
<td class="Botrule" align="center">72% (117/162)<br>[65%, 79%]</td>
<td class="Botrule" align="center">71% (120/170)<br>[63%, 77%]</td>
<td class="Botrule" align="center">(-9%, 12%)</td>
</tr>
</tbody>
</table>
<p><span class="Italics">H. pylori</span> eradication was defined as no positive test at 4 weeks following the end of treatment.  Patients must have had two tests performed, and these must have been negative to be considered eradicated of <span class="Italics">H. pylori</span>.  The following patients were excluded from the per-protocol analysis:  patients not infected with <span class="Italics">H. pylori  </span> prestudy, dropouts, patients with major protocol violations, patients with missing <span class="Italics">H. pylori</span> tests.  Patients excluded from the intent-to-treat analysis included those not infected with <span class="Italics">H. pylori</span> prestudy and those with missing <span class="Italics">H. pylori</span> tests prestudy.  Patients were assessed for <span class="Italics">H. pylori</span> eradication (4 weeks following treatment) regardless of their healing status (at the end of treatment).</p>
<p>The relationship between <span class="Italics">H. pylori</span> eradication and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence was assessed in a combined analysis of six  U.S. randomized, double-blind, multicenter, placebo-controlled trials using ranitidine bismuth citrate with or without antibiotics.  The results from approximately 650  U.S. patients showed that the risk of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> recurrence within 6 months of completing treatment was two times less likely in patients whose <span class="Italics">H. pylori  </span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was eradicated compared to patients in whom <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was not eradicated.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="GN78066"></a><a name="section-12.3.4.1"></a><p></p>
<h4>Safety</h4>
<p class="First">In clinical trials using combination therapy with clarithromycin plus ranitidine bismuth citrate, no adverse reactions peculiar to the combination of these drugs (using clarithromycin twice daily or three times a day) were observed.  Adverse reactions that have occurred have been limited to those reported with clarithromycin or ranitidine bismuth citrate.  (See <span class="Bold">ADVERSE REACTIONS</span> section of the Tritec package insert.)  The most frequent adverse experiences observed in clinical trials using combination therapy with clarithromycin (500 mg three times a day) with ranitidine bismuth citrate (n = 329) were <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span> (11%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3%).  The most frequent adverse experiences observed in clinical trials using combination therapy with clarithromycin (500 mg twice daily) with ranitidine bismuth citrate (n = 196) were <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span> (8%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (5%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4%).</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="GN78102"></a><a name="section-13"></a><p></p>
<h1>ANIMAL PHARMACOLOGY AND TOXICOLOGY</h1>
<p class="First">Clarithromycin is rapidly and well-absorbed with dose-linear kinetics, low protein binding, and a high volume of distribution.  Plasma half-life ranged from 1 to 6 hours and was species dependent.  High tissue concentrations were achieved, but negligible accumulation was observed.  Fecal clearance predominated.  Hepatotoxicity occurred in all species tested (i.e., in rats and monkeys at doses 2 times greater than and in dogs at doses comparable to the maximum human daily dose, based on mg/m<span class="Sup">2</span>).  Renal tubular degeneration (calculated on a mg/m<span class="Sup">2</span> basis) occurred in rats at doses 2 times, in monkeys at doses 8 times, and in dogs at doses 12 times greater than the maximum human daily dose.  <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">Testicular atrophy</span> (on a mg/m<span class="Sup">2</span> basis) occurred in rats at doses 7 times, in dogs at doses 3 times, and in monkeys at doses 8 times greater than the maximum human daily dose.  <span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">Corneal opacity</span> (on a mg/m<span class="Sup">2</span> basis) occurred in dogs at doses 12 times and in monkeys at doses 8 times greater than the maximum human daily dose.  Lymphoid depletion (on a mg/m<span class="Sup">2</span> basis) occurred in dogs at doses 3 times greater than and in monkeys at doses 2 times greater than the maximum human daily dose.  These adverse events were absent during clinical trials.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="GN78143"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>National Committee for Clinical Laboratory Standards, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition.  Approved Standard NCCLS Document M7-A4, Vol. 17, No. 2, NCCLS,  Wayne,  PA, January, 1997.</li>
<li>National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition.  Approved Standard NCCLS Document M2-A6, Vol. 17, No. 1, NCCLS,  Wayne,  PA, January, 1997.</li>
<li>National Committee for Clinical Laboratory Standards.  Summary Minutes, Subcommittee on Antimicrobial Susceptibility Testing,  Tampa,  FL.  January 11-13, 1998.</li>
<li>Chaisson RE, et al.  Clarithromycin and Ethambutol with or without Clofazimine for the Treatment of Bacteremic <span class="Italics">Mycobacterium avium</span> Complex Disease in Patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV Infection</span>.  AIDS.  1997;11:311-317.</li>
<li>Kemper CA, et al.  Treatment of <span class="Italics">Mycobacterium avium</span> Complex <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span> in AIDS with a Four-Drug Oral Regimen.  <span class="Italics">Ann Intern Med</span>.  1992;116:466-472.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN78196"></a><a name="section-15"></a><p></p>
<p class="First">Filmtab – Film-sealed tablets, Abbott</p>
<p>Biaxin Filmtab 250 mg and 500 mg and Biaxin XL 500 mg<br>Mfd. by Abbott Pharmaceuticals PR Ltd., Barceloneta, PR 00617</p>
<p>Biaxin Granules for Oral Suspension, 125mg/5mL and 250mg/5mL<br>Mfd. by Abbott Laboratories,  North Chicago,  IL   60064</p>
<p>For Abbott Laboratories,  North Chicago,  IL   60064, U.S.A.</p>
<p>Revised: 11/2011 Abbott Laboratories</p>
<br><p><br></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma      74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s37134224"></a><a name="section-16"></a><p></p>
<br><p class="First">NDC 54868-4191-0</p>
<p>20 Tablets</p>
<p>BIAXIN<span class="Sup">®</span> XL</p>
<p>FILMTAB<span class="Sup">®</span></p>
<p>clarithromycin extended-release tablets</p>
<p>500 mg</p>
<p>Rx only <br></p>
<div class="Figure"><img alt="image of 500 mg XL package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6&amp;name=4191.jpg"></div>
<br><br><br><p>NDC 54868-3384-0</p>
<p>100 mL (when mixed)</p>
<p>BIAXIN<span class="Sup">®</span> GRANULES</p>
<p>clarithromycin for oral suspension, USP</p>
<p>250 mg per 5 mL when reconstituted</p>
<p>Rx only <br></p>
<div class="Figure"><img alt="image of 250 mg / 5 mL package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6&amp;name=3384.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BIAXIN 		
					</strong><br><span class="contentTableReg">clarithromycin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3820(NDC:0074-3368)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLARITHROMYCIN</strong> (CLARITHROMYCIN) </td>
<td class="formItem">CLARITHROMYCIN</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>VANILLIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">KT</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3820-0</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-3820-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050662</td>
<td class="formItem">07/02/1996</td>
<td class="formItem">06/30/2011</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BIAXIN 		
					</strong><br><span class="contentTableReg">clarithromycin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-2338(NDC:0074-2586)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLARITHROMYCIN</strong> (CLARITHROMYCIN) </td>
<td class="formItem">CLARITHROMYCIN</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>VANILLIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">KL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-2338-0</td>
<td class="formItem">5  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-2338-1</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-2338-2</td>
<td class="formItem">14  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-2338-3</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-2338-4</td>
<td class="formItem">120  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:54868-2338-5</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:54868-2338-6</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">8</th>
<td class="formItem">NDC:54868-2338-7</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050662</td>
<td class="formItem">06/23/1993</td>
<td class="formItem">06/30/2011</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BIAXIN 		
					</strong><br><span class="contentTableReg">clarithromycin tablet, film coated, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4191(NDC:0074-3165)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLARITHROMYCIN</strong> (CLARITHROMYCIN) </td>
<td class="formItem">CLARITHROMYCIN</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>VANILLIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">KJ</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4191-0</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4191-1</td>
<td class="formItem">1  in 1 BOTTLE, DISPENSING</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">14  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050775</td>
<td class="formItem">11/03/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BIAXIN 		
					</strong><br><span class="contentTableReg">clarithromycin granule, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4919(NDC:0074-3163)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLARITHROMYCIN</strong> (CLARITHROMYCIN) </td>
<td class="formItem">CLARITHROMYCIN</td>
<td class="formItem">125 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM SORBATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">FRUIT PUNCH (Fruit Punch Flavor) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4919-0</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050698</td>
<td class="formItem">12/03/2003</td>
<td class="formItem">06/30/2011</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BIAXIN 		
					</strong><br><span class="contentTableReg">clarithromycin granule, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3384(NDC:0074-3188)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLARITHROMYCIN</strong> (CLARITHROMYCIN) </td>
<td class="formItem">CLARITHROMYCIN</td>
<td class="formItem">250 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM SORBATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">FRUIT PUNCH (Fruit Punch Flavor) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3384-0</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050698</td>
<td class="formItem">05/01/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>035934ee-0466-4e9f-b15d-1eba7aa748d2</div>
<div>Set id: 2e899f4a-a2e9-445c-a0ed-6ad811e997e6</div>
<div>Version: 1</div>
<div>Effective Time: 20120222</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
